Serina Therapeutics (SER) 10-K31 Mar 212020 FY Annual reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
Document and Entity Information - USD ($) $ in Thousands	Dec. 31, 2020	Mar. 26, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	AgeX Therapeutics, Inc.
Entity Central Index Key	0001708599
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 19,600
Entity Common Stock, Shares Outstanding		37,935,088
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 527	$ 2,352
Accounts and grants receivable, net	326	363
Prepaid expenses and other current assets	1,430	1,339
Total current assets	2,283	4,054
Property and equipment, net		1,126
Deposits and other long-term assets	50	111
Intangible assets, net	1,592	2,151
TOTAL ASSETS	3,925	7,442
CURRENT LIABILITIES
Accounts payable and accrued liabilities	1,656	1,582
Loan due to Juvenescence, net of debt issuance cost, current portion	1,960
Related party payables, net	71	64
Deferred revenues, current portion	275	283
Right-of-use lease liability		428
Paycheck Protection Program Loan	436
Insurance premium liability and other current liabilities	959	940
Total current liabilities	5,357	3,297
Loan due to Juvenescence, net of debt issuance cost, net of current portion	3,900	1,528
Deferred revenues, net of current portion	64
TOTAL LIABILITIES	9,321	4,825
Commitments and contingencies (Note 8)
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of December 31, 2020 and 2019
Common stock, $0.0001 par value, 100,000 shares authorized; 37,691 and 37,649 shares issued and outstanding as of December 31, 2020 and 2019, respectively	4	4
Additional paid-in capital	91,810	88,353
Accumulated other comprehensive income	143	69
Accumulated deficit	(97,073)	(86,208)
AgeX Therapeutics, Inc. stockholders' equity (deficit)	(5,116)	2,218
Noncontrolling interest	(280)	399
Total stockholders' equity (deficit)	(5,396)	2,617
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 3,925	$ 7,442

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,691,000	37,649,000
Common stock, shares outstanding	37,691,000	37,649,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
REVENUES:
Total revenues	$ 1,868	$ 1,728
Cost of sales	(158)	(244)
Gross profit	1,710	1,484
OPERATING EXPENSES:
Research and development	4,978	5,904
General and administrative	7,403	8,139
Total operating expenses	12,381	14,043
Loss from operations	(10,671)	(12,559)
OTHER INCOME (EXPENSES), NET:
Interest income (expense), net	(499)	29
Other income, net	44	294
Total other income (expense), net	(455)	323
NET LOSS BEFORE INCOME TAXES	(11,126)	(12,236)
Income tax provision benefit (expense)	150	(148)
NET LOSS	(10,976)	(12,384)
Net loss attributable to noncontrolling interest	111	230
NET LOSS ATTRIBUTABLE TO AGEX	$ (10,865)	$ (12,154)
NET LOSS PER COMMON SHARE: BASIC AND DILUTED	$ (0.29)	$ (0.33)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED	37,669,000	37,271,000
Subscription and Advertisement Revenues [Member]
REVENUES:
Total revenues	$ 1,265	$ 1,295
Grant Revenues [Member]
REVENUES:
Total revenues	307	180	[1]
Other Revenues [Member]
REVENUES:
Total revenues	$ 296	$ 253	[1]

[1]	A reclassification of $37,000 was made from subscription and advertisement revenues to other revenues to conform to current period presentation.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
NET LOSS	$ (10,976)	$ (12,384)
Other comprehensive income, net of tax:
Foreign currency translation adjustments	74	71
COMPREHENSIVE LOSS	(10,902)	(12,313)
Less: Comprehensive loss attributable to noncontrolling interest	111	230
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGEX COMMON STOCKHOLDERS	$ (10,791)	$ (12,083)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Accumulated Other Comprehensive Income [Member]	Total
Beginning balance at Dec. 31, 2018	$ 4	$ 81,499	$ (74,054)	$ 784	$ (2)	$ 8,231
Beginning balance, shares at Dec. 31, 2018	35,830,000
Issuance of common stock from exercise of warrants		4,500				4,500
Issuance of common stock from exercise of warrants, shares	1,800,000
Issuance of common stock to Juvenescence		56				56
Issuance of common stock to Juvenescence, shares	19,000
Issuance of warrants to Juvenescence		236				236
Stock-based compensation		1,907				1,907
Lapse of subsidiary options		155		(155)
Foreign currency translation adjustment					71	71
Net loss			(12,154)	(230)		(12,384)
Ending balance at Dec. 31, 2019	$ 4	88,353	(86,208)	399	69	2,617
Ending balance, shares at Dec. 31, 2019	37,649,000
Issuance of common stock to Juvenescence		37				37
Issuance of common stock to Juvenescence, shares	29,000
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes		(9)				(9)
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares	13,000
Issuance of warrants to Juvenescence		1,640				1,640
Stock-based compensation		933				933
Issuance of subsidiary common stock - LifeMap Sciences				288		288
Transactions with noncontrolling interests - LifeMap Sciences and ReCyte		856		(856)
Foreign currency translation adjustment					74	74
Net loss			(10,865)	(111)		(10,976)
Ending balance at Dec. 31, 2020	$ 4	$ 91,810	$ (97,073)	$ (280)	$ 143	$ (5,396)
Ending balance, shares at Dec. 31, 2020	37,691,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to AgeX	$ (10,865)	$ (12,154)
Net loss attributable to noncontrolling interest	(111)	(230)
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:
Gain on sale of equity method investment in Ascendance		(354)
Depreciation expense	699	91
Amortization of intangible assets	559	558
Amortization of right-of-use asset	424	302
Amortization of debt issuance cost	487	54
Stock-based compensation	933	1,907
Foreign currency remeasurement gain and other	119	76
Changes in operating assets and liabilities:
Accounts and grant receivables, net	10	(232)
Prepaid expenses and other current assets	839	473
Accounts payable and accrued liabilities	340	169
Related party payables	15	(68)
Insurance premium liability	(713)	(599)
Deferred revenues	57	(34)
Other current liabilities	(610)	(119)
Net cash used in operating activities	(7,817)	(10,160)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of equity method investment in Ascendance		354
Security deposit paid		(74)
Purchase of equipment and other	(20)	(641)
Net cash used in investing activities	(20)	(361)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants		4,500
Draw down on loan facility from Juvenescence	5,700	1,800
Proceeds from Paycheck Protection Program Loan	433
Payment of debt related costs	(157)
Repayment of financing lease liability	(15)	(35)
Net cash provided by financing activities	5,961	6,265
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	1	1
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(1,875)	(4,255)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
Beginning of year	2,452	6,707
End of year	577	2,452
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the year for interest	12	12
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES:
Issuance of common stock upon vesting of restricted stock units	21
Issuance of common stock to Juvenescence (Note 4)	37	56
Issuance of warrants to Juvenescence (Note 4)	$ 1,640	$ 236

Organization, Basis of Presenta

Organization, Basis of Presentation and Liquidity	12 Months Ended
Organization, Basis of Presentation and Liquidity	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Basis of Presentation and Liquidity	1. Organization, Basis of Presentation and Liquidity AgeX Therapeutics, Inc. (“AgeX”) was incorporated in January 2017 in the state of Delaware as a subsidiary of Lineage Cell Therapeutics, Inc. (“Lineage,” formerly known as BioTime, Inc.), a publicly traded, clinical-stage biotechnology company. AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions. AgeX’s proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows AgeX to utilize telomerase-expressing regenerative pluripotant stem cells (“PSCs”) for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. AgeX’s main technology platforms and product candidates are: ● PureStem ® ● UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells; ● AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes and obesity; ● AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia such as in peripheral vascular disease and ischemic heart disease; and ● Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair. AgeX is an “emerging growth company” as defined in the Jumpstart our Business Startups Act of 2012. Lineage’s sale of significant ownership interest in AgeX to Juvenescence On November 28, 2018 (the “Distribution Date”), Lineage distributed to its shareholders, on a pro rata basis, 12,697,028 shares of the AgeX common stock it then held (the “Distribution”). Immediately after the Distribution, Lineage retained 1,718,972 shares of AgeX common stock, representing approximately 4.8% of the common stock then issued and outstanding. Following the Distribution, AgeX common stock began publicly trading on the NYSE American under the symbol “AGE” (see Notes 4 and 7). Going Concern – Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have made certain adjustments to AgeX’s operating plans and budgets, including the staff reductions discussed below, to reduce its projected cash expenditures to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those adjustments, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $0.5 million as of December 31, 2020 plus the loan facility by Juvenescence to advance up to an additional $4.5 million to AgeX for operating capital discussed in Notes 4 and 9, would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the next twelve months from the issuance of these consolidated financial statements. These conditions raise substantial doubt about AgeX’s ability to continue as a going concern. AgeX will need to obtain substantial additional funding in connection with its continuing operations. Staff Reductions and Elimination of Laboratory Facilities Lease During April 2020, AgeX initiated staff layoffs that affected 11 research and development personnel. AgeX has paid approximately $105,000 in accrued payroll and unused paid time off and other benefits and recognized approximately $195,000 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits. The staff reductions followed AgeX’s strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic. Following the staff reductions, AgeX subleased out a significant portion of its leased laboratory space and did not renew its lease or enter into a new lease for a replacement facility when its lease expired on December 31, 2020. Instead, AgeX entered into a lease for a smaller office only space commencing January 1, 2021. Liquidity and impact of COVID-19 In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in development of its product candidates and technologies. The availability of financing may be adversely impacted by the COVID-19 pandemic which could continue to depress national and international economies and disrupt capital markets, supply chains, and aspects of AgeX’s operations. The extent to which the ongoing COVID-19 pandemic will ultimately impact AgeX’s business, results of operations, financial condition, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside AgeX’s control. The unavailability or inadequacy of financing to meet future capital needs could force AgeX to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. AgeX cannot assure that adequate financing will be available on favorable terms, if at all. Basis of presentation – The consolidated financial statements of AgeX are presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Through September 30, 2019, to the extent AgeX did not have its own employees or facilities for its operations, Lineage or Lineage commonly controlled and consolidated subsidiaries provided certain employees for administrative or operational services, including laboratory space and administrative facilities, as necessary, for the benefit of AgeX, under the Shared Facilities Agreement. Lineage allocated expenses such as salaries and payroll related expenses incurred and paid on behalf of AgeX based on the amount of time that particular employees devoted to AgeX affairs. Other expenses such as legal, accounting and financial reporting, marketing, and travel expenses were allocated to AgeX to the extent that those expenses were incurred by or on behalf of AgeX. Lineage also allocated certain overhead expenses such as rent and utilities, property taxes, insurance, laboratory expenses and supplies, telecommunications and other indirect expenses. These allocations were made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, headcount and percentage of personnel devoted to AgeX’s operations or management. Management evaluated the appropriateness of the allocations on a periodic basis and believes that this basis for allocation was reasonable. AgeX terminated the Shared Facilities Agreement effective September 30, 2019. Principles of consolidation – The following table reflects AgeX’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of December 31, 2020. Subsidiary Field of Business AgeX Ownership Country ReCyte Therapeutics Early stage pre-clinical research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, and ischemic conditions 94.8 % USA LifeMap Sciences (1) Biomedical, gene and disease databases and tools 80.7 % USA (1) On March 15, 2021, LifeMap Sciences was acquired by a third party in a cash-out merger. LifeMap Sciences includes LifeMap Sciences, Inc. and its wholly-owned subsidiary LifeMap Sciences, Ltd. an Israeli company which has discontinued operations, and proceedings have been commenced to dissolve the Israeli subsidiary. (See Note 9) All material intercompany accounts and transactions between AgeX and its subsidiaries have been eliminated in consolidation. Use of estimates – Reclassifications

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Going concern assessment – Cash and cash equivalents Concentrations of credit risk Fair value measurements Fair Value Measurements and Disclosures ● Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments. ● Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value. In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items. Accounts receivable, net – Equipment and furniture, net Long-lived intangible assets Impairment of long-lived assets – Transactions with noncontrolling interests of subsidiaries – Consolidation – Other Presentation Matters, Research and development – General and administrative Foreign currency translation and other comprehensive income or loss, foreign currency transaction gains and losses – For transactions denominated in other than the functional currency of AgeX or its subsidiaries, AgeX recognizes transaction gains and losses in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it. The majority of AgeX’s foreign currency transaction gains and losses were generated by LifeMap Sciences Ltd.’s intercompany payable due to LifeMap Sciences , Income taxes – Income Taxes However, the net operating losses and research and development credits generated before August 17, 2017, the contribution date to AgeX, will remain as tax attributes of Lineage (see Note 7). In general, net operating losses and other tax credit carryforwards generated by legal entities in a consolidated federal tax group or a combined state tax group, collectively “the tax group”, are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the tax group. However, under the Tax Matters Agreement between Lineage and AgeX entered into on August 17, 2017, any use of a member’s net operating loss and other tax credit carryforwards by the other member is subject to reimbursement by the benefiting member for the actual tax benefit realized. Since the August 30, 2018 deconsolidation of AgeX and to date, neither Lineage nor AgeX has used the tax attributes of the other. AgeX accounts for income taxes in accordance with ASC 740, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and enacted rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. AgeX’s judgments, estimates and projections regarding future taxable income may change over time due to changes, among other factors, in market conditions, changes in tax laws, and tax planning strategies. If AgeX’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on AgeX’s consolidated financial statements. The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. AgeX recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No unrecognized tax benefits have been recorded and no amounts were accrued for the payment of interest and penalties as of December 31, 2020 and 2019. AgeX does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. AgeX is currently unaware of any tax issues under review. On December 22, 2017, the United States enacted major federal tax reform legislation, Public Law No. 115-97, commonly referred to as the 2017 Tax Cuts and Jobs Act (“2017 Tax Act”), which enacted a broad range of changes to the Internal Revenue Code. Changes to taxes on corporations impacted by the 2017 Tax Act include, but not limited to, lowering the U.S. federal tax rates to a 21% flat tax rate, eliminating the corporate alternative minimum tax (“AMT”), imposing additional limitations on the deductibility of interest and net operating losses, allowing any net operating loss (“NOLs”) generated in tax years ending after December 31, 2017 to be carried forward indefinitely and generally repealing carrybacks, reducing the maximum deduction for NOL carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer’s taxable income, and allowing for additional expensing of certain capital expenditures. Future guidance from the Internal Revenue Service and other tax authorities may affect certain aspects of the 2017 Tax Act, for example, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and the Consolidated Appropriations Act, 2021 (“CAA”) modified certain provisions of the 2017 Tax Act. In addition, it is uncertain if and to what extent various states will conform to the 2017 Tax Act, the CARES Act or the CAA. The 2017 Tax Act also puts into effect a number of changes impacting operations outside of the United States including, but not limited to, the imposition of a one-time tax “deemed repatriation” on accumulated offshore earnings not previously subject to U.S. tax, and shifts the U.S taxation of multinational corporations from a worldwide system of taxation to a territorial system. ASC 740 requires the effects of changes in tax rates and laws on deferred tax balances (including the effects of the one-time transition tax) to be recognized in the period in which the legislation is enacted (see Note 7). On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to provide guidance for companies that are not able to complete their accounting for the income tax effects of the 2017 Tax Act in the period of enactment. SAB 118 allows AgeX to record provisional amounts during a measurement period not to extend beyond one year of the enactment date (see Note 7). AgeX applied the guidance in SAB 118 when accounting for the enactment-date effects of the 2017 Tax Act during the year ended December 31, 2018. As of December 31, 2018, AgeX completed its accounting for all the enactment-date income tax effects of the 2017 Tax Act further discussed in Note 7. Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2019, our foreign income inclusion was immaterial. For the year ended December 31, 2020, AgeX’s foreign entity operated at a book loss. However, for GILTI purposes, US tax laws are applied to the foreign activity and as a result there was an immaterial amount included in income for 2020. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred. Stock-based compensation – Compensation – Stock Compensation AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of Accounting Standards Update (“ASU”) 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09. AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under AgeX’s 2017 Equity Incentive Plan (the “Plan”). The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period. Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations. The Black-Scholes option pricing model requires AgeX to make certain assumptions including the fair value of the underlying common stock, the expected term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 6). The fair value of the shares of common stock underlying the stock options has historically been determined by the Board of Directors. Because there was no public market for AgeX’s common stock prior to November 29, 2018, the Board of Directors determined the fair value of the common stock at the time of the grant of options prior to that date by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, amongst other factors. The fair value was determined in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled Valuation of Privately Held Company Equity Securities Issued as Compensation The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. AgeX estimates the expected term of options granted using the “simplified method” provided under Staff Accounting Bulletin, Topic 14 Because AgeX’s common stock had no publicly traded history prior to November 29, 2018, for the years ended December 31, 2020 and 2019, AgeX estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options. The peer companies used include selected public companies within the biotechnology industry with comparable characteristics to AgeX, including similarity in size, lines of business, market capitalization, revenue and financial leverage. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of AgeX’s stock options. The dividend yield assumption is based on AgeX’s history and expectation of dividend payouts. AgeX has never declared or paid any cash dividends on its common stock, and AgeX does not anticipate paying any cash dividends in the foreseeable future. All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Stock-based compensation expense for the years ended December 31, 2020 and 2019 consists of stock-based compensation under the AgeX 2017 Equity Incentive Plan (Note 6) and stock-based compensation of AgeX’s subsidiaries that have their own stock option plans. As discussed above, certain of AgeX’s consolidated subsidiaries have their own share-based compensation plans. For share-based compensation awards granted by those privately-held consolidated subsidiaries under their respective equity plans, AgeX determines the fair value of the options granted under those plans using similar methodologies and assumptions AgeX used for its stock options discussed above. Although the fair value of stock options is determined in accordance with FASB guidance, changes in the assumptions and allocations can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements. Segments – Basic and diluted net loss per share attributable to common stockholders For the years ended December 31, 2020 and 2019, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive. The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands): Year Ended December 31, 2020 2019 Stock options 2,875 2,735 Warrants 1,473 58 Restricted stock units 37 41 Revenue recognition During the first quarter of 2018, AgeX adopted FASB ASU 2014-09, Revenues from Contracts with Customers (Topic 606) AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. In the applicable paragraphs below, AgeX has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606. Revenue recognition by source and geography The following table presents AgeX’s consolidated revenues disaggregated by source (in thousands). Year Ended December 31, REVENUES: 2020 2019 (1) Subscription and advertisement revenues $ 1,265 $ 1,295 Grant revenues 307 180 Other revenues 296 253 Total revenues $ 1,868 $ 1,728 (1) A reclassification of $37,000 was made from subscription and advertisement revenues to other revenues to conform to current period presentation. The following table presents consolidated revenues (in thousands), disaggregated by geography, based on the billing addresses of customers. Year Ended December 31, REVENUES: 2020 2019 United States $ 1,184 $ 986 Foreign 684 742 Total revenues $ 1,868 $ 1,728 Subscription and advertisement revenues ® ® LifeMap Sciences’ deferred subscription revenues primarily represent subscriptions for which cash payment was received for the subscription term, but the subscription term was not completed as of the balance sheet date reported. For the years ended December 31, 2020 and 2019, LifeMap Sciences recognized $1.3 million in each year in subscription and advertisement revenues. As of December 31, 2020, there was $339,000 included in deferred revenues in the consolidated balance sheets. LifeMap Sciences has licensed from third parties the databases and software it commercializes and has a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in cost of sales on the consolidated statements of operations when the cash is received and the royalty obligation is incurred as the royalty payments do not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers Grant revenues – Research and Development Arrangements In September 2018, AgeX was awarded a grant of up to approximately $225,000 from the National Institutes of Health (NIH). The NIH grant provided funding for continued development of AgeX technologies for treating osteoporosis. Grant funds were made available by the NIH as allowable expenses were incurred. For the years ended December 31, 2020 and 2019, AgeX incurred approximately $25,000 and $180,000, respectively, of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. As of March 31, 2020, AgeX expended the full amount available under this grant. On April 8, 2020, AgeX was awarded a grant of up to approximately $386,000 from the NIH. The NIH grant provides funding for continued development of AgeX’s technologies for treating stroke. The grant funds will be made available by the NIH to AgeX as allowable expenses are incurred. As of December 31, 2020, AgeX incurred approximately $282,000 of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. Arrangements with multiple performance obligations Leases On January 1, 2019, AgeX adopted ASU 2016-02, Leases Codification Improvements to Topic 842, Leases, Leases (Topic 842): Targeted improvements, AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Upon adoption of ASC 842 and based on the practical expedients available under that standard, AgeX did not reassess any expired or existing contracts, reassess the lease classification for any expired or existing leases and reassess initial direct costs for exiting leases. AgeX also elected not to capitalize leases that have terms of twelve months or less. AgeX’s sublease of its office and laboratory facility, which commenced on April 2, 2019 and ended on December 31, 2020, was subject to ASC 842. AgeX recognized its lease as a right-of-use asset included in property and equipment, net (see Note 3) and operating lease liability on its balance sheet in accordance with ASC 842 as of December 31, 2020 and 2019 (see Note 8). During 2019 and 2020, AgeX as a sublessor subleased portions of its office and laboratory space to certain unaffiliated third parties. These subleases are not accounted for under ASC 842 as amounts are not material and or the sublease periods are under one year. On November 3, 2020, AgeX entered into a one year lease effective January 1, 2021 for office space only comprising 135 square feet in a building in an office and research park at 1101 Marina Village Parkway, Suite 201, Alameda, California. This lease is not subject to ASC 842. Recently adopted accounting pronouncements In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement Recently issued accounting pronouncements not yet adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes On August 5, 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) CARES Act On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act, but does not expect it to have a material impact to its tax provision or its condensed consolidated financial statements. As described in Note 8, AgeX has obtained a loan under the Paycheck Protection Program under the CARES Act.

Selected Balance Sheet Componen

Selected Balance Sheet Components	12 Months Ended
Selected Balance Sheet Components	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Selected Balance Sheet Components	3. Selected Balance Sheet Components Property and equipment, net At December 31, 2020 and 2019, property and equipment was comprised of the following (in thousands): December 31, 2020 2019 Equipment, furniture and fixtures $ 381 $ 954 Right-of-use assets (1) - 726 Accumulated depreciation and amortization (381 ) (554 ) Property and equipment, net $ - $ 1,126 (1) AgeX adopted ASC 842 on January 1, 2019. For additional information on this standard and right-of-use assets and liabilities, see Notes 2 and 8. Depreciation and amortization expense amounted to $1,123,000 and $393,000 for the years ended December 31, 2020 and 2019, respectively. Accumulated depreciation and amortization also reflects a $21,000 adjustment upon the sale of laboratory equipment; write off of right-of-use assets in the amount of $726,000 and leasehold improvements of $436,000 which were fully amortized as of December 31, 2020 following termination of the facility lease agreement on that date; and also write off of other fixed asset in the amount of approximately $112,000 primarily comprised of $89,000 for the write off of office furniture and equipment with the shutdown of our subsidiary’s office in Israel. Furthermore, depreciation expense in 2020 included $210,000 of accelerated depreciation expense primarily of laboratory equipment given the uncertainty of reinstitution of research and development work in-house. As a result of the layoffs of mostly research personnel in April 2020 and the expiration of the AgeX laboratory facility lease on December 31, 2020, research and development work have been scaled back and contracted out to third party service providers. Intangible assets, net Intangible assets, net are primarily comprised of acquired licenses and other rights by LifeMap Sciences from a third party for certain databases it commercializes. On August 13, 2018, AgeX entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Escape Therapeutics, Inc. (“Escape”) pursuant to which AgeX acquired certain patents and patent applications related primarily to methods of modifying cells and tissues and certain pluripotent stem cell lines so as to reduce their risk of being rejected when transplanted. This technology is called “UniverCyte™”. AgeX paid Escape $1,072,436 in cash and issued 80,000 shares of AgeX common stock, with an approximate value of $240,000, for aggregate acquisition cost of $1.3 million for the UniverCyte™ assets. The Purchase Agreement was considered an asset acquisition rather than a business combination in accordance with ASC 805-50, Business Combinations ASC 730-10-25(c), Research and Development – Intangible Assets Purchased from Others In addition to the purchase price, AgeX will pay Escape a royalty of less than 1% on net sales of products, processes and services under the acquired patents, if the assets are commercialized. Additional shares of AgeX common stock totaling up to $4.3 million of market value will also be issued to Escape upon the attainment of development and regulatory approval milestones by AgeX for each product covered by the acquired patents. Contingent consideration in an asset acquisition is generally recorded when probable and estimable in accordance with ASC 450, Contingencies AgeX has also agreed to engage Escape’s chief executive officer as a consultant for a period of up to three years to assist AgeX in utilizing the acquired patents. AgeX pays $200,000 per year in consulting fees as services are performed included in research and development expenses. At December 31, 2020 and 2019, intangible assets, primarily consisting of acquired in-process research and development and patents, and accumulated amortization were as follows (in thousands): December 31, 2020 2019 Intangible assets $ 5,586 $ 5,586 Accumulated amortization (3,994 ) (3,435 ) Intangible assets, net $ 1,592 $ 2,151 AgeX recognized $559,000 and $558,000 in amortization expense of intangible assets, included in research and development expenses, for the years ended December 31, 2020 and 2019, respectively. Accounts payable and accrued liabilities At December 31, 2020 and 2019, accounts payable and accrued liabilities were comprised of the following (in thousands): December 31, 2020 2019 Accounts payable $ 761 $ 420 Accrued compensation 228 263 Accrued vendors and other expenses 667 899 Accounts payable and accrued liabilities $ 1,656 $ 1,582

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	4. Related Party Transactions Shared Facilities and Service Agreement On August 17, 2017, AgeX and Lineage executed the Shared Facilities Agreement. The Shared Facilities Agreement was terminated by AgeX effective September 30, 2019. Under the terms of the Shared Facilities Agreement, Lineage agreed to permit AgeX to use Lineage’s Alameda, California office and laboratory facilities and certain equipment for the purpose of conducting business. Lineage also provided accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other administrative services to AgeX. Lineage charged AgeX a “Use Fee” for services received and usage of facilities, equipment, and supplies. For each billing period, Lineage prorated and allocated costs incurred as a Use Fee to AgeX. Such costs generally included services of Lineage employees, consultants, and contractors; equipment use, insurance, lease expense, fees for services of accountants, lawyers, and other professionals; software; supplies; and utilities. Allocation depended on key cost drivers including actual documented use, square footage of facilities used, time spent, costs incurred by or for AgeX, or upon proportionate usage by Lineage and AgeX, as reasonably estimated by Lineage. Lineage charged AgeX a 5% markup on such allocated costs under the terms of the Shared Facilities Agreement. The allocated cost of Lineage employees and contractors who provided services was based upon records maintained of the number of hours or percentage of time of such personnel devoted to the performance of services. The Use Fee was determined and invoiced to AgeX on a monthly basis for each calendar month of each calendar year. In addition to the Use Fees, AgeX reimbursed Lineage for any out of pocket costs incurred by Lineage for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of AgeX. The Shared Facilities Agreement was not considered a lease under the provisions of ASC 842 discussed in Note 2, because, among other factors, a significant part of the Shared Facilities Agreement is a contract for services, not a tangible asset, and is cancelable by either party without penalty. In aggregate, Lineage charged such Use Fees to AgeX and subsidiaries as follows (in thousands): Year Ended December 31, 2019 Research and development $ 701 General and administrative 239 Total Use Fees $ 940 AgeX has accounted for payables to an affiliate, net of receivables from that affiliate, if any, for shared services and other transactions that AgeX has entered into with that affiliate. AgeX recorded those payables and receivables on a net basis where AgeX and the affiliate intended to exercise a right of offset of the payable and the receivable and to settle the balances net by having the party that owes the other party pay the net balance owed. AgeX has treated Lineage and Juvenescence as affiliates for this purpose. AgeX had nil and $7,000 in related party receivables from Lineage, included in related party payables, net on the consolidated balance sheets as of December 31, 2020 and 2019, respectively. Transactions with Juvenescence On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence has agreed to provide to AgeX an $8.0 million line of credit for a period of 18 months on substantially the same terms as the Loan Agreement described below, except that (a) all loans to AgeX under the 2020 Loan Agreement in excess of an initial $500,000 advance are subject to Juvenescence’s discretion, (b) AgeX may not draw more than $1 million in any single draw, (c) in lieu of accrued interest, AgeX will issue to Juvenescence 28,500 shares of AgeX common stock when AgeX has borrowed an aggregate of $3 million under the 2020 Loan Agreement, (d) AgeX will issue to Juvenescence warrants to purchase shares of AgeX common stock (“New Warrants”) in amounts determined by the warrant formula described below, (e) the Repayment Date for outstanding principal balance of the loan under the 2020 Loan Agreement will be March 30, 2023, (f) if AgeX requests additional loans after making the first two draws of funds (which are expected to total $1 million) under the 2020 Loan Agreement, a Security and Pledge Agreement (the “Security Agreement”) will go into effect granting Juvenescence a security interest in all of the assets of AgeX and AgeX’s subsidiaries ReCyte Therapeutics and Reverse Bioengineering, Inc. (the “Guarantor Subsidiaries” or each a “Guarantor Subsidiary”) (g) the Guarantor Subsidiaries will guarantee AgeX’s obligations under the 2020 Loan Agreement if AgeX makes more than two draws of funds under the 2020 Loan Agreement and (h) Juvenescence has the right to convert the principal amount of outstanding loans under the 2020 Loan Agreement into shares of AgeX common stock at the Market Price as defined in the 2020 Loan Agreement. Further, in addition to the Events of Default described herein, additional Events of Default will arise under the 2020 Loan Agreement if (i) AgeX or any of the Guarantor Subsidiaries sells, leases, licenses, consigns, transfers, or otherwise disposes of a material part of its assets other than inventory in the ordinary course of business or certain intercompany transactions, or certain other limited permitted transactions, unless Juvenescence approves, (ii) the security interests under the Security Agreement, if in effect, are not valid or perfected, or AgeX or a Guarantor Subsidiary contests the validity of its obligations under the 2020 Loan Agreement or Security Agreement or other related agreement with Juvenescence, or there is a loss, theft, damage or destruction of a material portion of the collateral, (iii) any representation, warranty, or other statement made by AgeX or a Guarantor Subsidiary under the 2020 Loan Agreement is incomplete, untrue, incorrect, or misleading, or (iv) AgeX or a Guarantor Subsidiary suspends or ceases to carry on all or a material part of its business or threatens to do so. On July 21, 2020, AgeX and Juvenescence entered into an amendment to the 2020 Loan Agreement that waived (i) certain provisions requiring that, as a condition to the funding of a third draw of funds, AgeX and the Guarantor Subsidiaries execute a Security Agreement and related documents pledging certain assets as collateral, and (ii) certain provisions providing that the Guarantor Subsidiaries would guarantee AgeX’s obligations under the 2020 Loan Agreement, in each case subject to an acknowledgement by AgeX and the Guarantor Subsidiaries that Juvenescence may, in its discretion, condition any advances under the 2020 Loan Agreement subsequent to the third draw of funds on the receipt of such collateral agreements and guarantees. In addition, the 2020 Loan Agreement and the related Warrant Agreement were amended to place certain limits on the number of shares that may be issued to Juvenescence upon conversion of outstanding loan amounts or exercise of the warrants, in order to comply with applicable NYSE American listing requirements. AgeX may not draw down funds if an “Event of Default” under the 2020 Loan Agreement has occurred and is continuing and AgeX may not draw down more than $1.0 million in any single draw. In accordance with the terms of the 2020 Loan Agreement, AgeX issued to Juvenescence 28,500 shares of AgeX common stock on July 27, 2020. Each time AgeX receives an advance of funds under the 2020 Loan Agreement and the New Warrants and underlying shares as registrable securities under the Registration Rights Agreement. On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence has provided to AgeX a $2.0 million line of credit for a period of 18 months. As of December 31, 2020, AgeX had drawn the full $2.0 million line of credit. See Note 9 for information concerning an amendment to the 2019 Loan Agreement that extended the date for repayment of the loan and increased the line of credit by an additional $4.0 million. In lieu of accrued interest, AgeX issued to Juvenescence 19,000 shares of AgeX common stock, with an approximate value of $56,000, concurrently with the first draw down of funds under the Loan Agreement. However, if AgeX fails to repay the loan when due, interest at the rate of 10% per annum, compounded daily, will accrue on the unpaid balance from the date the payment was due. In lieu of repayment of funds borrowed, AgeX or Juvenescence may convert the loan balance (including principal and accrued interest, if any) into AgeX common stock or “units” if AgeX consummates a “Qualified Offering” which means a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $7.5 million. Events of Default under the Loan Agreement include: (i) AgeX fails to pay any amount in the manner and at the time provided in the Loan Agreement and the failure to pay is not remedied within 10 business days; (ii) AgeX fails to perform any of its obligations under the Loan Agreement and if the failure can be remedied it is not remedied to the satisfaction of Juvenescence within 10 business days after notice to AgeX; (iii) other indebtedness for money borrowed in excess of $100,000 becomes due and payable or can be declared due and payable prior to its due date or if indebtedness for money borrowed in excess of $25,000 is not paid when due; (iv) AgeX stops payment of its debts generally or discontinues its business or becomes unable to pay its debts as they become due or enters into any arrangement with creditors generally, (v) AgeX becoming insolvent or in liquidation or administration or other insolvency procedures, or a receiver, trustee or similar officer is appointed in respect of all or any part of its assets and such appointment continues undischarged or unstayed for sixty days, (vi) it becomes illegal for AgeX to perform its obligations under the Loan Agreement or any governmental permit, license, consent, exemption or similar requirement for AgeX to perform its obligations under the Loan Agreement or to carry out its business is not obtained or ceases to remain in effect; (vii) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX if such process is not released, vacated or fully bonded within sixty calendar days after its issue or levy; (viii) any injunction, order or judgement of any court is entered or issued which in the opinion of Juvenescence materially and adversely affects the ability of AgeX to carry out its business or to pay amounts owed to Juvenescence under the Loan Agreement, and (ix) there is a change in AgeX’s financial condition that in the opinion of Juvenescence materially and adversely affects, or is likely to so affect, its ability to perform any of its obligations under the Loan Agreement. As consideration for the line of credit under the Loan Agreement, AgeX issued to Juvenescence warrants to purchase 150,000 shares of AgeX common stock. The exercise price of the warrants is $2.60 per share, which was the volume weighted average price on the NYSE American (VWAP) of AgeX common stock over the twenty trading days prior to the date the warrants were issued. The warrants will expire at 5:00 p.m. New York time three years after the date of issue. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events. The estimated value of these warrants was $236,000 which was determined in accordance with the Black-Scholes option pricing model with inputs as specified in the relevant warrant agreement. AgeX has entered into a Registration Rights Agreement to use commercially reasonable efforts to register the 19,000 shares issuable under the Loan Agreement and the 150,000 warrants and underlying shares for resale under the Securities Act of 1933, as amended (the “Securities Act”), upon request of Juvenescence if Form S-3 is available to AgeX. Juvenescence will also have “piggy-back” registration rights if AgeX files a registration statement for the sale of shares for itself or other stockholders. AgeX will bear the expenses of the registration statement but not underwriting or broker’s commissions related to the sale of warrants or shares. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, is devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $280,000. As of December 31, 2020 and 2019, AgeX had approximately $71,000 payable to Juvenescence for COO services rendered included in related party payables, net on the consolidated balance sheets. Sale and exercise of warrants by AgeX In February 2018, AgeX sold warrants, as described in Note 5, to certain investors, including to Alfred D. Kingsley, who was at the time AgeX’s Executive Chairman and the Chairman of Lineage’s Board of Directors. On March 18, 2019, Mr. Kingsley purchased a total of 248,600 shares of AgeX common stock through the exercise of his warrants at an exercise price of $2.50 per share and paid a total purchase price of $621,500.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2020
Equity [Abstract]
Stockholders' Equity	5. Stockholders’ Equity Preferred Stock AgeX is authorized to issue up to 5,000,000 shares of $0.0001 par value preferred stock. To date, no preferred shares are issued and outstanding. Common Stock AgeX has 100,000,000 shares of $0.0001 par value common stock authorized. The holders of AgeX’s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of AgeX common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of AgeX outstanding preferred shares, if any. The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of AgeX stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable. As of December 31, 2020 and 2019, there were 37,691,047 and 37,649,000 shares of AgeX common stock issued and outstanding, respectively. Issuance and Sale of Warrants by AgeX Through December 31, 2020, as consideration for $5.5 million in loans made to AgeX under the 2020 Loan Agreement, AgeX issued to Juvenescence warrants to purchase 2,769,299 shares of AgeX common stock. AgeX also issued 28,500 shares of AgeX common stock upon receipt of funds from the loan draw made on July 27, 2020. See Note 4. On August 13, 2019, in lieu of accrued interest under the Loan Agreement, AgeX issued to Juvenescence 19,000 shares of AgeX common stock concurrently with the first draw down of loan funds. Furthermore, as consideration for the line of credit under the Loan Agreement, AgeX issued to Juvenescence warrants to purchase 150,000 shares of AgeX common stock. See Note 4. On February 28, 2018, AgeX sold Warrants to purchase 1,473,600 shares of AgeX common stock for $0.50 per Warrant for aggregate cash proceeds to AgeX of $736,800, which included $124,300 from Alfred D. Kingsley, AgeX’s then Executive Chairman and the Chairman of Lineage’s Board of Directors. On July 10, 2018, AgeX sold additional Warrants to purchase 526,400 shares of common stock for $0.50 per warrant for aggregate net cash proceeds to AgeX of $263,200. The Warrants were exercisable at $2.50 per share. On March 18, 2019, holders of the Warrants purchased a total of 1,800,000 shares of AgeX common stock through the exercise of Warrants at an exercise price of $2.50 per share, for total proceeds to AgeX of $4.5 million. Any unexercised Warrants expired on that date.

Stock-Based Awards

Stock-Based Awards	12 Months Ended
Stock-Based Awards	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Awards	6. Stock-Based Awards Equity Incentive Plan Under the 2017 Equity Incentive Plan (the “Plan”), AgeX reserved 4,000,000 shares of common stock for the grant of stock options or the sale of restricted stock (“Restricted Stock”) or for the settlement of hypothetical units issued with reference to common stock (“Restricted Stock Units”). AgeX may also grant stock appreciation rights (“SARs”) under the Plan. The Plan also permits AgeX to issue such other securities as its Board of Directors (the “Board”) or the Compensation Committee (the “Committee”) administering the Plan may determine. Awards of stock options, Restricted Stock, SARs, and Restricted Stock Units (“Awards”) may be granted under the Plan to AgeX employees, directors, and consultants. Awards may vest and thereby become exercisable or have restrictions on forfeiture lapse on the date of grant or in periodic installments or upon the attainment of performance goals, or upon the occurrence of specified events. No person shall be granted, during any one year period, options to purchase, or SARs with respect to, more than 1,000,000 shares in the aggregate, or any Awards of Restricted Stock or Restricted Stock Units with respect to more than 500,000 shares in the aggregate. If an Award is to be settled in cash, the number of shares on which the Award is based shall not count toward the individual share limit. No Awards may be granted under the Plan more than ten years after the date upon which the Plan was adopted by the Board, and no options or SARS granted under the Plan may be exercised after the expiration of ten years from the date of grant. Stock Options Options granted under the Plan may be either “incentive stock options” within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (the “Code”), or “non-qualified” stock options that do not qualify incentive stock options. Incentive stock options may be granted only to AgeX employees and employees of subsidiaries. The exercise price of stock options granted under the Plan must be equal to the fair market of AgeX common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of AgeX stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $100,000. The exercise price of an option may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board or Committee may approve. Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter, but in the case of the termination of an employee, director, or consultant’s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option. Restricted Stock and Restricted Stock Units In lieu of granting options, AgeX may enter into purchase agreements with employees under which they may purchase or otherwise acquire Restricted Stock or Restricted Stock Units subject to such vesting, transfer, and repurchase terms, and other restrictions. The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value. Employees or consultants, but not executive officers or directors, who purchase Restricted Stock may be permitted to pay for their shares by delivering a promissory note or an installment payment agreement that may be secured by a pledge of their Restricted Stock. Restricted Stock may also be issued for services actually performed by the recipient prior to the issuance of the Restricted Stock. Unvested Restricted Stock for which AgeX has not received payment may be forfeited, or AgeX may have the right to repurchase unvested shares upon the occurrence of specified events, such as termination of employment. Subject to the restrictions set with respect to the particular Award, a recipient of Restricted Stock generally shall have the rights and privileges of a stockholder, including the right to vote the Restricted Stock and the right to receive dividends; provided that, any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld for the recipient’s account, and interest may be credited on the amount of the cash dividends withheld. The cash dividends or stock dividends so withheld and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) shall be distributed to the recipient in cash or, at the discretion of the Board or Committee, in shares of common stock having a fair market value equal to the amount of such dividends, if applicable, upon the release of restrictions on the Restricted Stock and, if the Restricted Stock is forfeited, the recipient shall have no right to the dividends. The terms and conditions of a grant of Restricted Stock Units shall be determined by the Board or Committee. No shares of common stock shall be issued at the time a Restricted Stock Unit is granted. A recipient of Restricted Stock Units shall have no voting rights with respect to the Restricted Stock Units. Upon the expiration of the restrictions applicable to a Restricted Stock Unit, AgeX will either issue to the recipient, without charge, one share of common stock per Restricted Stock Unit or cash in an amount equal to the fair market value of one share of common stock. At the discretion of the Board or Committee, each Restricted Stock Unit (representing one share of common stock) may be credited with cash and stock dividends paid in respect of one share (“Dividend Equivalents”). Dividend Equivalents shall be withheld for the recipient’s account, and interest may be credited on the amount of cash Dividend Equivalents withheld. Dividend Equivalents credited to a recipient’s account and attributable to any particular Restricted Stock Unit (and earnings thereon, if applicable) shall be distributed in cash or in shares of common stock having a fair market value equal to the amount of the Dividend Equivalents and earnings, if applicable, upon settlement of the Restricted Stock Unit. If a Restricted Stock Unit is forfeited, the recipient shall have no right to the related Dividend Equivalents. SARs An SAR is the right to receive, upon exercise, an amount payable in cash or shares, or a combination of shares and cash, equal to the number of shares subject to the SAR that is being exercised, multiplied by the excess of (a) the fair market value of a common stock on the date the SAR is exercised, over (b) the exercise price specified in the SAR Award agreement. SARs may be granted either as free standing SARs or in tandem with options. No SAR may be exercised later than 10 years after the date of grant. The exercise price of an SAR shall not be less than 100% of the fair market value of one share of common stock on the date of grant. An SAR granted in conjunction with an option shall have the same exercise price as the related option, shall be transferable only upon the same terms and conditions as the related option, and shall be exercisable only to the same extent as the related option; provided, however, that the SAR by its terms shall be exercisable only when the fair market value per share exceeds the exercise price per share of the SAR or related option. Upon any exercise of an SAR granted in tandem with an option, the number of shares for which the related option shall be exercisable shall be reduced by the number of shares for which the SAR has been exercised. The number of shares for which an SAR issued in tandem with an option shall be exercisable shall be reduced by the number of shares for which the related option has been exercised. Equity Incentive Plan Awards A summary of the Plan activity and related information follows (in thousands except weighted average exercise price): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price January 1, 2019 1,731 2,269 - $ 2.42 Restricted stock units granted (100) - 50 - Options granted (677) 677 - 3.92 Options forfeited and cancelled 100 (100) - 3.48 December 31, 2019 1,054 2,846 50 2.74 Options granted (303) 303 - 0.74 Options expired/forfeited 295 (295) - 2.89 Restricted stock units vested - - (22) - December 31, 2020 1,046 2,854 28 $ 2.51 Options exercisable at December 31, 2020 1,954 $ 2.59 There were no exercises of stock options during the years ended December 31, 2020 and 2019. Total proceeds if all options granted and outstanding as of December 31, 2020 were exercised would be approximately $7.2 million. At December 31, 2020, AgeX had approximately $1.5 million of total unrecognized compensation expense related to the Plan that will be recognized over a weighted-average period of 2.01 years. The aggregate intrinsic value of options outstanding was $239,000 and options exercisable was $2,000 as of December 31, 2020. Stock-based Compensation Expense AgeX recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the years ended December 31, 2020 and 2019 (in thousands): Year Ended December 31, 2020 2019 Research and development $ 82 $ 133 General and administrative 851 1,774 Total stock-based compensation expense $ 933 $ 1,907 The weighted-average estimated fair value of stock options granted during the years ended December 31, 2020 and 2019 was $0.53 per share and $2.45 per share, respectively, using the Black-Scholes option pricing model with the following weighted-average assumptions: Year Ended December 31, 2020 2019 Expected life (in years) 6.08 6.01 Risk-free interest rates 0.45% 1.96% Volatility 87.86% 74.53% Dividend yield -% -% The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If AgeX had made different assumptions, its stock-based compensation expense and net loss for the years ended December 31, 2020 and 2019 may have been significantly different. See Note 2 for a discussion of the factors used in determining these assumptions. AgeX does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes Net loss from continuing operations before provision for income taxes are as follows: December 31, 2020 2019 Domestic $ (9,358 ) (13,051 ) Foreign (1,768 ) 815 Net loss before income tax provision $ (11,126 ) (12,236 ) The provision (benefit) for income taxes consisted of the following (in thousands): December 31, 2020 2019 Current tax provision: U.S. federal $ - $ - State - - Foreign (150 ) 148 Total current provision (150 ) 148 Deferred tax provision (benefit): U.S. federal - - State - - Foreign - - Total deferred provision (benefit) - - Provision (benefit) for income taxes $ (150 ) $ 148 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The primary components of the net deferred tax assets and liabilities as of December 31, 2020 and 2019 were as follows (in thousands): December 31, Deferred tax assets/(liabilities): 2020 2019 Net operating loss carryforwards $ 13,958 $ 12,402 Research and development credit carryforwards 2,306 2,069 Patents and fixed assets 693 454 Stock-based compensation 687 659 Operating lease liability - 428 Other, net 184 124 Operating lease ROU assets - (424 ) Valuation allowance (17,828 ) (15,712 ) Total net deferred tax assets $ - $ - A valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. Income taxes differed from the amounts computed by applying the U.S. federal income tax rate indicated to pretax losses from operations as a result of the following: December 31, 2020 2019 Computed tax benefit at federal statutory rate 21% 21% Research and development and other credits 1% 1% State tax benefit, net of effect on federal income taxes 2% 5% Permanent differences (2)% -% Tax effect attributable to foreign operations (2)% -% Change in valuation allowance (19)% (28)% 1% (1)% As of December 31, 2020, AgeX has net operating loss carryforwards of approximately $49.2 million for U.S. federal income tax purposes. Of this amount, $8.9 million is attributable to LifeMap Sciences, which includes $2.7 million in NOLs generated while it was included in the consolidated tax group and would be available to offset income of AgeX in the future. The remaining LifeMap Sciences’ NOLs of $6.2 million are attributable to NOLs generated for the tax years during which LifeMap Sciences filed a separate federal income tax return and, accordingly, those NOLs are available only to LifeMap Sciences’ taxable income within AgeX in future years. In general, NOLs and other tax credit carryforwards generated by legal entities in a consolidated federal tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the consolidated federal tax group. However, under the Tax Matters Agreement between Lineage and AgeX, any use of a member’s NOLs and other tax credit carryforwards by the other member is subject to reimbursement by the benefiting member for the actual tax benefit realized. Since the August 30, 2018 deconsolidation of AgeX and to date, neither Lineage nor AgeX has used the tax attributes of the other. On March 23, 2018, Ascendance was acquired by a third party in a merger through which AgeX received approximately $3.2 million in cash for its shares of Ascendance common stock. For financial reporting purposes, AgeX recognized a $3.2 million gain on the sale of its equity method investment in Ascendance. The sale was a taxable transaction to AgeX generating a taxable gain of approximately $2.2 million. AgeX had sufficient current year losses from operations to offset the entire gain resulting in no income taxes due. At the close of the merger, $955,000 of cash that otherwise would have been payable to the Ascendance stockholders on a pro rata basis based on share ownership was deposited into an escrow account where it was held through the term of the escrow, which expired in June 2019. The funds were held in the escrow account to cover certain potential indemnity payments and other obligations that might arise after the merger. During 2019, the escrow funds were paid to the former Ascendance shareholders and AgeX received $354,000 as its pro rata share of the funds as additional proceeds from the sale of its Ascendance investment included in other income (expense), net, for the year ended December 31, 2019. AgeX has sufficient current year losses from operations to offset this gain resulting in no income taxes due. As further discussed in Note 1, on August 30, 2018, Lineage consummated the sale of 14,400,000 shares of AgeX common stock to Juvenescence. AgeX received no proceeds from that transaction because the shares sold were owned by Lineage. Prior to the transaction, Juvenescence owned 5.6% of AgeX’s issued and outstanding common stock. Upon completion of the transaction, Lineage’s ownership in AgeX was reduced from 80.4% to 40.2% of AgeX’s issued and outstanding shares of common stock, and Juvenescence’s ownership in AgeX was increased from 5.6% to 45.8% of AgeX’s issued and outstanding shares of common stock. Accordingly, since August 31, 2018, AgeX has not been included in Lineage’s consolidated federal and state income tax returns and AgeX has filed its own, standalone income tax returns with its subsidiaries. As of December 31, 2020, AgeX has net operating losses of approximately $41.0 million for California purposes. As AgeX and its subsidiaries have been included in the combined California tax return with Lineage, up to the date of deconsolidation on August 30, 2018, those state net operating losses will remain with AgeX. In general, NOLs and other tax credit carryforwards generated by legal entities in a combined state tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the combined state tax group. However, under the Tax Matters Agreement between Lineage and AgeX, any use of a member’s NOLs and other tax credit carryforwards by the other member is subject to reimbursement by the benefiting member for the actual tax benefit realized. Federal net operating losses generated on or prior to December 31, 2017, expire in varying amounts between 2028 and 2037, while federal net operating losses generated after December 31, 2017, carryforward indefinitely. The state net operating losses expire in varying amounts between 2028 and 2040. As of December 31, 2020, AgeX has research and development tax credit carryforwards for federal and state tax purposes of $1.3 million and $1.0 million, respectively. Although this LifeMap Sciences credit has been included as part of the AgeX credit carryforwards, LifeMap Sciences filed a separate federal income tax return prior to January 1, 2018 and its prior research credit carryforwards may not be used to offset federal taxable income of AgeX. As AgeX and its subsidiaries were included in the California combined return with Lineage, these credits noted above will remain with AgeX. The federal tax credits expire between 2028 and 2040, while the state tax credits have no expiration date. Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2019, our foreign income inclusion was immaterial. For the year ended December 31, 2020, AgeX’s foreign entity operated at a book loss. However, for GILTI purposes, US tax laws are applied to the foreign activity and as a result there was an immaterial amount included in income for 2020. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred. For the year ended December 31, 2020, we experienced a domestic loss from continuing operations and a foreign loss. Although we did not record a domestic provision or benefit, we did record a foreign benefit for income taxes, due to an adjustment in the prior year's foreign tax provision reported. Other Income Tax Matters Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by net operating loss (“NOL”) carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. AgeX and its subsidiaries may be subject to potential income tax examination by U.S. federal or states authorities. These potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws. AgeX filed its first consolidated federal tax return in 2018. For AgeX subsidiaries that did operate and filed separate tax returns prior to 2018, those entities are not subject to tax examination by major taxing authorities for tax years before 2016. However, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years by AgeX or any of its subsidiaries. Any potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Lease Agreement On April 2, 2019, the term of a sublease that AgeX entered into during March 2019 (the “AgeX Lease”) went into effect for an office and research facility (the “Alameda Facility”) comprising approximately 23,911 square feet of space in a building in an office and research park at 965 Atlantic Avenue, Alameda, California that served as AgeX’s principal offices and research laboratory. Base monthly rent was $35,866.50 for the initial 12 months of the sublease term and then increased to $36,942.50. In addition, AgeX paid real property taxes, insurance and operating expenses pertaining to the building in which the Alameda Facility is located. The AgeX Lease expired on December 31, 2020. In connection with the AgeX Lease, as of December 31, 2019 AgeX incurred $436,000 in tenant improvement expenses that it funded and completed in November 2019. This amount was fully amortized and written off upon lease termination as of December 31, 2020. Subleases During 2019, AgeX, as a sublessor, entered into sublease agreements (the “AgeX Subleases”) with unrelated parties (the “Sublessees”) to lease approximately 11,121 square feet of space at AgeX’s Alameda Facility. The first Sublessee paid AgeX $3,088.50 per month and the second Sublessee paid AgeX $15,405.40 per month for the first twelve months of the AgeX Sublease and $16,311.60 per month for the remaining duration of the AgeX Subleases. The AgeX Subleases expired on December 31, 2020. Adoption of ASC 842 The tables below provide the amounts recorded in connection with the adoption of ASC 842 as of, and during, the year ended December 31, 2020, for the AgeX Lease. AgeX recorded a right-of-use asset of $726,000 and a right-of-use liability for the same amount for the AgeX Lease in April 2019, which is considered a noncash investing activity. The following table presents supplemental cash flow information related to the AgeX Lease for the years ended December 31, 2020 and 2019 (in thousands): Year Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating lease $ 441 $ 323 The following table presents supplemental balance sheet information related to the AgeX Lease as of December 31, 2020 and 2019 (in thousands, except lease term and discount rate): December 31, 2020 (1) 2019 Operating lease Right-of-use asset, net $ - $ 424 Right-of-use lease liability $ - $ 428 Weighted average remaining lease term Operating lease 0 years 1 year Weighted average discount rate Operating lease 6.0 % 6.0 % (1) The right-of-use asset and right-of-use lease liability were fully amortized and written off as of December 31, 2020 upon termination of the AgeX Lease. There were no future minimum lease commitments as of December 31, 2020. Litigation – General AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations. Employment Contracts AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations. Indemnification In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s pre-clinical programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s pre-clinical programs. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to AgeX’s pre-clinical programs. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. The term of these indemnification obligations will generally continue in effect after the termination or expiration of the particular research, development, services, license, or lease agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements as of December 31, 2020 and 2019. PPP Loan On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from Axos Bank (the “Bank”) under the Paycheck Protection Program (the “PPP Loan”). The PPP loan will bear interest at a rate of 1% per annum. No payments will be due on the PPP loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP loan, monthly payments of principal and interest will be due, in an amount required to fully amortize the principal amount outstanding on the PPP loan by the maturity date. The maturity date is April 13, 2022. On December 27, 2020, the Consolidated Appropriations Act, 2021 (CAA) was signed into law, retroactively allowing a deduction of the expenses that gave rise to the PPP loan forgiveness, that was previously denied under the CARES Act. California has partially adopted the federal tax treatment. On February 17, 2021, California issued an Immediate Action Agreement, allowing companies to deduct up to $150,000 in expenses covered by the PPP loan. The principal amount of the PPP loan is subject to forgiveness under the PPP to the extent that PPP loan proceeds are used to pay expense permitted by the PPP, including payroll, rent, and utilities (collectively, “Qualifying Expenses”), during the time frame permitted by the PPP. AgeX used the PPP loan amount for Qualifying Expenses and believes that all or a substantial portion of the PPP loan may be forgiven within one year and has classified the loan as current as of December 31, 2020. On February 19, 2021, the PPP loan was forgiven in full. Notice of Delisting On June 1, 2020, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan. The Exchange staff will review AgeX’s compliance with the Compliance Plan on a quarterly basis and if AgeX does not show progress consistent with the Compliance Plan or is not in compliance with the Exchange’s continued listing standards by December 1, 2021, the Exchange will commence delisting procedures. If the Exchange staff determines that AgeX is not in compliance with the Compliance Plan at any time, the Exchange staff will promptly initiate delisting proceedings. AgeX intends to make arrangements to have its common stock quoted on the OTC Bulletin Board if its common stock is delisted from the Exchange.

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events Office Lease Agreement Effective January 1, 2021, AgeX relocated its principal offices to 1101 Marina Village Parkway, Suite 201, Alameda, California following the December 31, 2020 expiration of the Alameda Lease. AgeX’s new office occupies 135 square feet of leased space in a building located in an office and research park. Base monthly rent is $947 for the one year lease term and also covers office furniture rental, janitorial services, utilities and internet service. Additional Draws under the 2020 Loan Agreement During January 2021, AgeX borrowed an additional $2.0 million under the 2020 Loan Agreement with Juvenescence. The outstanding principal balance of the loans under the 2020 Loan Agreement will become due and payable on the Repayment Date on March 30, 2023. Amendment to 2019 Loan Agreement and Registration Rights Agreements On February 10, 2021, AgeX entered into an amendment (the “Amendment”) to the 2019 Loan Agreement. The Amendment extends the maturity date of loans under the 2019 Loan Agreement to February 14, 2022 and increases the amount of the loan facility from $2.0 million to $6.0 million, of which AgeX has previously borrowed $2 million. All loans in excess of the initial $2.0 million that AgeX previously borrowed are subject to Juvenescence’s discretion. Additional loans, if made, will be in denominations of $1.0 million. The Amendment also grants Juvenescence the right to convert the principal amount of outstanding loans under the 2019 Loan Agreement, as amended, into shares of AgeX common stock at the Market Price as defined in the Amendment. The Amendment places certain limits on the number of shares that may be issued upon conversion of outstanding loan amounts by Juvenescence, or by AgeX under AgeX’s loan conversion rights, if under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of the shares. Under those limits (a) the number of shares of common stock that may be issued upon conversion of any loan advance, at a conversion price that is lower than the market price of AgeX common stock at the time of funding the applicable advance being converted, may not exceed 19.9% of the shares outstanding at August 13, 2019, and (b) no advances may be converted into common stock in an amount that would cause Juvenescence’s ownership of AgeX common stock to equal or exceed 50% of the number of shares of AgeX common stock then outstanding. AgeX will pay Juvenescence an Origination Fee in the amount of $160,000 upon the earlier of the repayment of the loan by AgeX or the conversion of the loan balance into AgeX common stock by Juvenescence or by AgeX. The Origination Fee will be paid in shares of AgeX common stock rather than cash if AgeX exercises its right to convert the loan into shares of common stock, or if Juvenescence elects to convert the loan in shares of common stock and elects to receive the Origination Fee in AgeX common stock. In connection with the Amendment, AgeX entered into Amendment No. 2 to its Registration Rights Agreement with Juvenescence to include among the shares of AgeX common stock to which Juvenescence has registration rights any shares of common stock that may be issued to Juvenescence upon conversion of the loans under the 2019 Loan Agreement, as amended, or under the 2020 Loan Agreement. Under the Registration Rights Agreement, as amended, AgeX agreed to register for resale under the Securities Act, shares of AgeX common stock that were issued to Juvenescence pursuant to the 2019 Loan Agreement or the 2020 Loan Agreement, or that may be acquired by Juvenescence upon conversion of the loans into common stock, or upon exercise of certain common stock purchase warrants that were issued to Juvenescence pursuant to the 2019 Loan Agreement and the 2020 Loan Agreement. PPP Loan Forgiveness On February 19, 2021, the PPP loan was forgiven in full. See Note 8. Proposed Merger On March 2, 2021, we announced that AgeX and LyGenesis, Inc. (“LyGenesis”), a privately held biotechnology company developing cell therapies that enable organ regeneration, will proceed to negotiate an agreement for a merger of the two companies. LyGenesis recently received U.S. Food and Drug Administration clearance for its Investigational New Drug application to conduct a Phase 2a clinical trial on the safety, tolerability, and efficacy of its lead cell therapy for patients with end-stage liver disease, with study initiation planned for 2021. Based on the terms currently being discussed, a newly formed subsidiary of AgeX would merge into LyGenesis. At the closing of the merger, AgeX would issue to LyGenesis stockholders a number of shares of AgeX common stock representing two-thirds of the total number of shares of AgeX common stock to be outstanding immediately following the consummation of the merger on a fully diluted basis, but prior to the issuance of additional shares in a contemplated capital raising transaction following the execution of a merger agreement and contingent on the closing of the merger. Under the terms being discussed, if the merger is completed, AgeX’s pre-merger stockholders would receive an 80% economic interest in AgeX’s induced tissue regeneration or iTR technology; the terms and structure of such economic interest have not yet been determined. There can be no assurance that the negotiations between AgeX and LyGenesis will result in the execution of a definitive merger agreement on the terms being discussed or at all, or, if a merger agreement is entered into, that the merger will be consummated. The completion of any merger would be subject to approval by a special independent committee of the AgeX Board of Directors and by the respective Boards of Directors of both companies. The merger would also be subject to approval by AgeX stockholders and LyGenesis stockholders, including in each case approval by both a majority of the outstanding shares and by the holders of a majority of the shares not held by Juvenescence Limited. Juvenescence, the largest shareholder of AgeX, is also the largest shareholder of LyGenesis. Juvenescence beneficially owns approximately 52.7% of the AgeX common stock determined as disclosed in its most recent amendment to its Schedule 13D filed with the Securities and Exchange Commission, and owns approximately 48% of the common stock of LyGenesis (assuming the conversion of its convertible debt into equity). The Chairman of AgeX’s Board of Directors, Dr. Gregory Bailey, is the Chief Executive Officer of Juvenescence. Two directors of LyGenesis, James Mellon and David Ellam, are the Chairman and the Chief Financial Officer of Juvenescence, respectively. LifeMap Sciences Merger On March 6, 2021, AgeX and its majority-owned subsidiary LifeMap Sciences entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Atlas Capital Partners Limited, a British Virgin Islands company limited by shares (“Atlas”), and GCLMS Acquisition Corporation (“GCLMS”), a Delaware corporation that was a wholly-owned subsidiary of Atlas. On March 15, 2021, the merger was completed pursuant to the terms of the Merger Agreement. As a result of the merger GCLMS merged into LifeMap Sciences and (a) the shares of LifeMap Sciences common stock outstanding at the time of the merger entitled the holders of those shares to receive a pro rata portion of a $500,000 cash payment for all shares of LifeMap Sciences common stock in the aggregate (the “Merger Consideration”), with each LifeMap Sciences shareholder’s pro rata portion of the Merger Consideration to be determined in accordance with the number of shares of LifeMap Sciences common stock owned by such shareholder as a percentage of shares of LifeMap Sciences common stock outstanding immediately before the effective date of the merger, and (b) the outstanding shares of GCLMS common stock were converted into shares of LifeMap Sciences common stock so that Atlas is now the sole shareholder of LifeMap Sciences. AgeX received approximately $466,400 in cash as its pro rata share of the Merger Consideration in the merger. Prior to and as a condition to the merger under the terms of the Merger Agreement $1,761,296 of LifeMap Sciences’ indebtedness to AgeX was converted into shares of LifeMap Sciences common stock. LifeMap Sciences also paid AgeX $250,000 in cash to pay off a portion of LifeMap Sciences’ indebtedness to AgeX that was not converted into shares of LifeMap Sciences common stock. At-the-market Offering On January 8, 2021 AgeX entered into a sales agreement with Chardan Capital Markets LLC (“Chardan”), relating to the sale of shares of AgeX common stock, par value $0.0001 per share, through an at-the-market (“ATM”) offering as described in the prospectus supplement filed with the Form S-3 which was declared effective by the SEC on January 29, 2021. In accordance with the terms of the sales agreement, AgeX may offer and sell shares of AgeX common stock having an aggregate offering price of up to $12.6 million from time to time through Chardan, acting as the sales agent. Through March 26, 2021, AgeX raised approximately $496,000 in gross proceeds under the ATM.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2020
Accounting Policies [Abstract]
Going Concern Assessment	Going concern assessment –
Cash and Cash Equivalents	Cash and cash equivalents
Concentrations of Credit Risk	Concentrations of credit risk
Fair Value Measurements	Fair value measurements Fair Value Measurements and Disclosures ● Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments. ● Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value. In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items.
Accounts Receivable, Net	Accounts receivable, net –
Equipment and Furniture, Net	Equipment and furniture, net
Long-Lived Intangible Assets	Long-lived intangible assets
Impairment of Long-Lived Assets	Impairment of long-lived assets –
Transactions with Noncontrolling Interests of Subsidiaries	Transactions with noncontrolling interests of subsidiaries – Consolidation – Other Presentation Matters,
Research and Development	Research and development –
General and Administrative	General and administrative
Foreign Currency Translation and Other Comprehensive Income or Loss, Foreign Currency Transaction Gains and Losses	Foreign currency translation and other comprehensive income or loss, foreign currency transaction gains and losses – For transactions denominated in other than the functional currency of AgeX or its subsidiaries, AgeX recognizes transaction gains and losses in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it. The majority of AgeX’s foreign currency transaction gains and losses were generated by LifeMap Sciences Ltd.’s intercompany payable due to LifeMap Sciences ,
Income Taxes	Income taxes – Income Taxes However, the net operating losses and research and development credits generated before August 17, 2017, the contribution date to AgeX, will remain as tax attributes of Lineage (see Note 7). In general, net operating losses and other tax credit carryforwards generated by legal entities in a consolidated federal tax group or a combined state tax group, collectively “the tax group”, are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the tax group. However, under the Tax Matters Agreement between Lineage and AgeX entered into on August 17, 2017, any use of a member’s net operating loss and other tax credit carryforwards by the other member is subject to reimbursement by the benefiting member for the actual tax benefit realized. Since the August 30, 2018 deconsolidation of AgeX and to date, neither Lineage nor AgeX has used the tax attributes of the other. AgeX accounts for income taxes in accordance with ASC 740, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and enacted rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. AgeX’s judgments, estimates and projections regarding future taxable income may change over time due to changes, among other factors, in market conditions, changes in tax laws, and tax planning strategies. If AgeX’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on AgeX’s consolidated financial statements. The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. AgeX recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No unrecognized tax benefits have been recorded and no amounts were accrued for the payment of interest and penalties as of December 31, 2020 and 2019. AgeX does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. AgeX is currently unaware of any tax issues under review. On December 22, 2017, the United States enacted major federal tax reform legislation, Public Law No. 115-97, commonly referred to as the 2017 Tax Cuts and Jobs Act (“2017 Tax Act”), which enacted a broad range of changes to the Internal Revenue Code. Changes to taxes on corporations impacted by the 2017 Tax Act include, but not limited to, lowering the U.S. federal tax rates to a 21% flat tax rate, eliminating the corporate alternative minimum tax (“AMT”), imposing additional limitations on the deductibility of interest and net operating losses, allowing any net operating loss (“NOLs”) generated in tax years ending after December 31, 2017 to be carried forward indefinitely and generally repealing carrybacks, reducing the maximum deduction for NOL carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer’s taxable income, and allowing for additional expensing of certain capital expenditures. Future guidance from the Internal Revenue Service and other tax authorities may affect certain aspects of the 2017 Tax Act, for example, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and the Consolidated Appropriations Act, 2021 (“CAA”) modified certain provisions of the 2017 Tax Act. In addition, it is uncertain if and to what extent various states will conform to the 2017 Tax Act, the CARES Act or the CAA. The 2017 Tax Act also puts into effect a number of changes impacting operations outside of the United States including, but not limited to, the imposition of a one-time tax “deemed repatriation” on accumulated offshore earnings not previously subject to U.S. tax, and shifts the U.S taxation of multinational corporations from a worldwide system of taxation to a territorial system. ASC 740 requires the effects of changes in tax rates and laws on deferred tax balances (including the effects of the one-time transition tax) to be recognized in the period in which the legislation is enacted (see Note 7). On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to provide guidance for companies that are not able to complete their accounting for the income tax effects of the 2017 Tax Act in the period of enactment. SAB 118 allows AgeX to record provisional amounts during a measurement period not to extend beyond one year of the enactment date (see Note 7). AgeX applied the guidance in SAB 118 when accounting for the enactment-date effects of the 2017 Tax Act during the year ended December 31, 2018. As of December 31, 2018, AgeX completed its accounting for all the enactment-date income tax effects of the 2017 Tax Act further discussed in Note 7. Beginning in 2018, the 2017 Tax Act subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2019, our foreign income inclusion was immaterial. For the year ended December 31, 2020, AgeX’s foreign entity operated at a book loss. However, for GILTI purposes, US tax laws are applied to the foreign activity and as a result there was an immaterial amount included in income for 2020. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred.
Stock-Based Compensation	Stock-based compensation – Compensation – Stock Compensation AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of Accounting Standards Update (“ASU”) 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09. AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under AgeX’s 2017 Equity Incentive Plan (the “Plan”). The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period. Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations. The Black-Scholes option pricing model requires AgeX to make certain assumptions including the fair value of the underlying common stock, the expected term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 6). The fair value of the shares of common stock underlying the stock options has historically been determined by the Board of Directors. Because there was no public market for AgeX’s common stock prior to November 29, 2018, the Board of Directors determined the fair value of the common stock at the time of the grant of options prior to that date by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, amongst other factors. The fair value was determined in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled Valuation of Privately Held Company Equity Securities Issued as Compensation The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. AgeX estimates the expected term of options granted using the “simplified method” provided under Staff Accounting Bulletin, Topic 14 Because AgeX’s common stock had no publicly traded history prior to November 29, 2018, for the years ended December 31, 2020 and 2019, AgeX estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options. The peer companies used include selected public companies within the biotechnology industry with comparable characteristics to AgeX, including similarity in size, lines of business, market capitalization, revenue and financial leverage. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of AgeX’s stock options. The dividend yield assumption is based on AgeX’s history and expectation of dividend payouts. AgeX has never declared or paid any cash dividends on its common stock, and AgeX does not anticipate paying any cash dividends in the foreseeable future. All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Stock-based compensation expense for the years ended December 31, 2020 and 2019 consists of stock-based compensation under the AgeX 2017 Equity Incentive Plan (Note 6) and stock-based compensation of AgeX’s subsidiaries that have their own stock option plans. As discussed above, certain of AgeX’s consolidated subsidiaries have their own share-based compensation plans. For share-based compensation awards granted by those privately-held consolidated subsidiaries under their respective equity plans, AgeX determines the fair value of the options granted under those plans using similar methodologies and assumptions AgeX used for its stock options discussed above. Although the fair value of stock options is determined in accordance with FASB guidance, changes in the assumptions and allocations can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.
Segments	Segments –
Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	Basic and diluted net loss per share attributable to common stockholders For the years ended December 31, 2020 and 2019, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive. The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands): Year Ended December 31, 2020 2019 Stock options 2,875 2,735 Warrants 1,473 58 Restricted stock units 37 41
Revenue Recognition	Revenue recognition During the first quarter of 2018, AgeX adopted FASB ASU 2014-09, Revenues from Contracts with Customers (Topic 606) AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. In the applicable paragraphs below, AgeX has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606. Revenue recognition by source and geography The following table presents AgeX’s consolidated revenues disaggregated by source (in thousands). Year Ended December 31, REVENUES: 2020 2019 (1) Subscription and advertisement revenues $ 1,265 $ 1,295 Grant revenues 307 180 Other revenues 296 253 Total revenues $ 1,868 $ 1,728 (1) A reclassification of $37,000 was made from subscription and advertisement revenues to other revenues to conform to current period presentation. The following table presents consolidated revenues (in thousands), disaggregated by geography, based on the billing addresses of customers. Year Ended December 31, REVENUES: 2020 2019 United States $ 1,184 $ 986 Foreign 684 742 Total revenues $ 1,868 $ 1,728 Subscription and advertisement revenues ® ® LifeMap Sciences’ deferred subscription revenues primarily represent subscriptions for which cash payment was received for the subscription term, but the subscription term was not completed as of the balance sheet date reported. For the years ended December 31, 2020 and 2019, LifeMap Sciences recognized $1.3 million in each year in subscription and advertisement revenues. As of December 31, 2020, there was $339,000 included in deferred revenues in the consolidated balance sheets. LifeMap Sciences has licensed from third parties the databases and software it commercializes and has a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in cost of sales on the consolidated statements of operations when the cash is received and the royalty obligation is incurred as the royalty payments do not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers Grant revenues – Research and Development Arrangements In September 2018, AgeX was awarded a grant of up to approximately $225,000 from the National Institutes of Health (NIH). The NIH grant provided funding for continued development of AgeX technologies for treating osteoporosis. Grant funds were made available by the NIH as allowable expenses were incurred. For the years ended December 31, 2020 and 2019, AgeX incurred approximately $25,000 and $180,000, respectively, of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. As of March 31, 2020, AgeX expended the full amount available under this grant. On April 8, 2020, AgeX was awarded a grant of up to approximately $386,000 from the NIH. The NIH grant provides funding for continued development of AgeX’s technologies for treating stroke. The grant funds will be made available by the NIH to AgeX as allowable expenses are incurred. As of December 31, 2020, AgeX incurred approximately $282,000 of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. Arrangements with multiple performance obligations
Leases	Leases On January 1, 2019, AgeX adopted ASU 2016-02, Leases Codification Improvements to Topic 842, Leases, Leases (Topic 842): Targeted improvements, AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Upon adoption of ASC 842 and based on the practical expedients available under that standard, AgeX did not reassess any expired or existing contracts, reassess the lease classification for any expired or existing leases and reassess initial direct costs for exiting leases. AgeX also elected not to capitalize leases that have terms of twelve months or less. AgeX’s sublease of its office and laboratory facility, which commenced on April 2, 2019 and ended on December 31, 2020, was subject to ASC 842. AgeX recognized its lease as a right-of-use asset included in property and equipment, net (see Note 3) and operating lease liability on its balance sheet in accordance with ASC 842 as of December 31, 2020 and 2019 (see Note 8). During 2019 and 2020, AgeX as a sublessor subleased portions of its office and laboratory space to certain unaffiliated third parties. These subleases are not accounted for under ASC 842 as amounts are not material and or the sublease periods are under one year. On November 3, 2020, AgeX entered into a one year lease effective January 1, 2021 for office space only comprising 135 square feet in a building in an office and research park at 1101 Marina Village Parkway, Suite 201, Alameda, California. This lease is not subject to ASC 842.
Recently Adopted Accounting Pronouncements	Recently adopted accounting pronouncements In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently issued accounting pronouncements not yet adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes On August 5, 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)
CARES Act	CARES Act On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act, but does not expect it to have a material impact to its tax provision or its condensed consolidated financial statements. As described in Note 8, AgeX has obtained a loan under the Paycheck Protection Program under the CARES Act.

Organization, Basis of Presen_2

Organization, Basis of Presentation and Liquidity (Tables)	12 Months Ended
Organization, Basis of Presentation and Liquidity (Tables)	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Ownership of Outstanding Shares of Its Subsidiaries	The following table reflects AgeX’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of December 31, 2020. Subsidiary Field of Business AgeX Ownership Country ReCyte Therapeutics Early stage pre-clinical research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, and ischemic conditions 94.8 % USA LifeMap Sciences (1) Biomedical, gene and disease databases and tools 80.7 % USA (1) On March 15, 2021, LifeMap Sciences was acquired by a third party in a cash-out merger. LifeMap Sciences includes LifeMap Sciences, Inc. and its wholly-owned subsidiary LifeMap Sciences, Ltd. an Israeli company which has discontinued operations, and proceedings have been commenced to dissolve the Israeli subsidiary. (See Note 9)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands): Year Ended December 31, 2020 2019 Stock options 2,875 2,735 Warrants 1,473 58 Restricted stock units 37 41
Schedule of Disaggregated Revenues	The following table presents AgeX’s consolidated revenues disaggregated by source (in thousands). Year Ended December 31, REVENUES: 2020 2019 (1) Subscription and advertisement revenues $ 1,265 $ 1,295 Grant revenues 307 180 Other revenues 296 253 Total revenues $ 1,868 $ 1,728 (1) A reclassification of $37,000 was made from subscription and advertisement revenues to other revenues to conform to current period presentation.
Schedule of Disaggregated by Geographical Revenue	The following table presents consolidated revenues (in thousands), disaggregated by geography, based on the billing addresses of customers. Year Ended December 31, REVENUES: 2020 2019 United States $ 1,184 $ 986 Foreign 684 742 Total revenues $ 1,868 $ 1,728

Selected Balance Sheet Compon_2

Selected Balance Sheet Components (Tables)	12 Months Ended
Selected Balance Sheet Components (Tables)	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Schedule of Property and Equipment, Net, and Construction in Progress	At December 31, 2020 and 2019, property and equipment was comprised of the following (in thousands): December 31, 2020 2019 Equipment, furniture and fixtures $ 381 $ 954 Right-of-use assets (1) - 726 Accumulated depreciation and amortization (381 ) (554 ) Property and equipment, net $ - $ 1,126 (1) AgeX adopted ASC 842 on January 1, 2019. For additional information on this standard and right-of-use assets and liabilities, see Notes 2 and 8.
Schedule of Intangible Assets, Net	At December 31, 2020 and 2019, intangible assets, primarily consisting of acquired in-process research and development and patents, and accumulated amortization were as follows (in thousands): December 31, 2020 2019 Intangible assets $ 5,586 $ 5,586 Accumulated amortization (3,994 ) (3,435 ) Intangible assets, net $ 1,592 $ 2,151
Schedule of Accounts Payable and Accrued Liabilities	At December 31, 2020 and 2019, accounts payable and accrued liabilities were comprised of the following (in thousands): December 31, 2020 2019 Accounts payable $ 761 $ 420 Accrued compensation 228 263 Accrued vendors and other expenses 667 899 Accounts payable and accrued liabilities $ 1,656 $ 1,582

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Dec. 31, 2020
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	In aggregate, Lineage charged such Use Fees to AgeX and subsidiaries as follows (in thousands): Year Ended December 31, 2019 Research and development $ 701 General and administrative 239 Total Use Fees $ 940

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	12 Months Ended
Stock-Based Awards (Tables)	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of the Plan activity and related information follows (in thousands except weighted average exercise price): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price January 1, 2019 1,731 2,269 - $ 2.42 Restricted stock units granted (100) - 50 - Options granted (677) 677 - 3.92 Options forfeited and cancelled 100 (100) - 3.48 December 31, 2019 1,054 2,846 50 2.74 Options granted (303) 303 - 0.74 Options expired/forfeited 295 (295) - 2.89 Restricted stock units vested - - (22) - December 31, 2020 1,046 2,854 28 $ 2.51 Options exercisable at December 31, 2020 1,954 $ 2.59
Schedule of Stock Based Compensation Expense	AgeX recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the years ended December 31, 2020 and 2019 (in thousands): Year Ended December 31, 2020 2019 Research and development $ 82 $ 133 General and administrative 851 1,774 Total stock-based compensation expense $ 933 $ 1,907
Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options	The weighted-average estimated fair value of stock options granted during the years ended December 31, 2020 and 2019 was $0.53 per share and $2.45 per share, respectively, using the Black-Scholes option pricing model with the following weighted-average assumptions: Year Ended December 31, 2020 2019 Expected life (in years) 6.08 6.01 Risk-free interest rates 0.45% 1.96% Volatility 87.86% 74.53% Dividend yield -% -%

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Net Loss from Continuing Operations Before Provision for Income Taxes	Net loss from continuing operations before provision for income taxes are as follows: December 31, 2020 2019 Domestic $ (9,358 ) (13,051 ) Foreign (1,768 ) 815 Net loss before income tax provision $ (11,126 ) (12,236 )
Schedule of Current and Deferred Tax Provision (Benefit) for Income Taxes	The provision (benefit) for income taxes consisted of the following (in thousands): December 31, 2020 2019 Current tax provision: U.S. federal $ - $ - State - - Foreign (150 ) 148 Total current provision (150 ) 148 Deferred tax provision (benefit): U.S. federal - - State - - Foreign - - Total deferred provision (benefit) - - Provision (benefit) for income taxes $ (150 ) $ 148
Schedule of Components of Deferred Tax Assets and Liabilities	The primary components of the net deferred tax assets and liabilities as of December 31, 2020 and 2019 were as follows (in thousands): December 31, Deferred tax assets/(liabilities): 2020 2019 Net operating loss carryforwards $ 13,958 $ 12,402 Research and development credit carryforwards 2,306 2,069 Patents and fixed assets 693 454 Stock-based compensation 687 659 Operating lease liability - 428 Other, net 184 124 Operating lease ROU assets - (424 ) Valuation allowance (17,828 ) (15,712 ) Total net deferred tax assets $ - $ -
Schedule of Income Tax Rate Reconciliation	Income taxes differed from the amounts computed by applying the U.S. federal income tax rate indicated to pretax losses from operations as a result of the following: December 31, 2020 2019 Computed tax benefit at federal statutory rate 21% 21% Research and development and other credits 1% 1% State tax benefit, net of effect on federal income taxes 2% 5% Permanent differences (2)% -% Tax effect attributable to foreign operations (2)% -% Change in valuation allowance (19)% (28)% 1% (1)%

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Supplemental Cash Flow Information Related to Operating Lease	The following table presents supplemental cash flow information related to the AgeX Lease for the years ended December 31, 2020 and 2019 (in thousands): Year Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating lease $ 441 $ 323
Schedule of Supplemental Balance Sheet Information Related to Operating Lease	The following table presents supplemental balance sheet information related to the AgeX Lease as of December 31, 2020 and 2019 (in thousands, except lease term and discount rate): December 31, 2020 (1) 2019 Operating lease Right-of-use asset, net $ - $ 424 Right-of-use lease liability $ - $ 428 Weighted average remaining lease term Operating lease 0 years 1 year Weighted average discount rate Operating lease 6.0 % 6.0 % (1) The right-of-use asset and right-of-use lease liability were fully amortized and written off as of December 31, 2020 upon termination of the AgeX Lease.

Organization, Basis of Presen_3

Organization, Basis of Presentation and Liquidity (Details Narrative) $ in Thousands	Nov. 28, 2018shares	Aug. 30, 2018shares	Apr. 30, 2020USD ($)Integer	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)shares
Accumulated deficit				$ 97,073	$ 86,208
Cash and cash equivalents				$ 527	$ 2,352
Number of staff layoffs \| Integer			11
Accrued payroll			$ 105
Restructuring charges			$ 195
Common Stock [Member]
Ownership interest	4.80%
Number of common stock shares issued \| shares				29,000	19,000
Retained shares of common stock \| shares	1,718,972
Lineage [Member]
Percentage of ownership before transaction		80.40%
Percentage of ownership after transaction		40.20%
Lineage [Member] \| Pro Rata Basis [Member] \| Common Stock [Member]
Number of common stock shares issued \| shares	12,697,028
Juvenescence Limited [Member]
Number of share sold \| shares		14,400,000
Ownership interest		5.60%
Percentage of ownership before transaction		5.60%
Percentage of ownership after transaction		45.80%
Juvenescence Limited [Member] \| Loan Facility Agreement [Member]
Line of credit facility				$ 4,500

Organization, Basis of Presen_4

Organization, Basis of Presentation and Liquidity - Schedule of Ownership of Outstanding Shares of Its Subsidiaries (Details)	12 Months Ended
	Dec. 31, 2020
ReCyte Therapeutics, Inc. [Member]
Field of Business	Early stage pre-clinical research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, and ischemic conditions
Agex Ownership	94.80%
Country	USA
LifeMap Sciences, Inc. [Member]
Field of Business	Biomedical, gene and disease databases and tools	[1]
Agex Ownership	80.70%	[1]
Country	USA	[1]

[1]	On March 15, 2021, LifeMap Sciences was acquired by a third party in a cash-out merger. LifeMap Sciences includes LifeMap Sciences, Inc. and its wholly-owned subsidiary LifeMap Sciences, Ltd. an Israeli company which has discontinued operations, and proceedings have been commenced to dissolve the Israeli subsidiary. (See Note 9)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	Apr. 08, 2018	Sep. 30, 2018	Dec. 31, 2020	Dec. 31, 2019
Cash and cash equivalents			$ 527	$ 2,352
Accounts receivable, allowance for doubtful accounts				321
Estimated useful life of long lived assets			10 years
Payment of interest and penalties
Uncertain tax position
Federal tax rates			21.00%	21.00%
Income tax likelihood, description			The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company's pre-GILTI U.S. income.
Revenues			$ 1,868	$ 1,728
Lease description			For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.
LifeMap Sciences [Member]
Deferred revenues			$ 339
National Institutes of Health [Member] \| For Treating Osteoporosis [Member]
Allowable expenses of grant revenues			25	180
National Institutes of Health [Member] \| For Treating Stroke [Member]
Allowable expenses of grant revenues			282
Subscription and Advertisement Revenues [Member]
Revenues			1,265	1,295
Subscription and Advertisement Revenues [Member] \| LifeMap Sciences [Member]
Revenues			1,300	1,300
Grant Revenues [Member]
Revenues	$ 386		$ 307	$ 180	[1]
Grant Revenues [Member] \| National Institutes of Health [Member]
Revenues		$ 225
Minimum [Member]
Estimated useful life			3 years
Maximum [Member]
Estimated useful life			10 years

[1]	A reclassification of $37,000 was made from subscription and advertisement revenues to other revenues to conform to current period presentation.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Stock Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount		2,875,000	2,735,000
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share, amount	[1]	1,473,000	58,000
Restricted Stock Units [Member]
Antidilutive securities excluded from computation of earnings per share, amount		37,000	41,000

[1]	AgeX issued Juvenescence warrants to purchase 2,638,401 shares of AgeX common stock as consideration for the line of credit under the Loan Agreements discussed in Note 4.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Disaggregated Revenues (Details) - USD ($) $ in Thousands	Apr. 08, 2018	Dec. 31, 2020	Dec. 31, 2019
Total revenues		$ 1,868	$ 1,728
Subscription and Advertisement [Member]
Total revenues		1,265	1,295
Grant Revenues [Member]
Total revenues	$ 386	307	180	[1]
Other Revenues [Member]
Total revenues		$ 296	$ 253	[1]

[1]	A reclassification of $37,000 was made from subscription and advertisement revenues to other revenues to conform to current period presentation.

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Disaggregated Revenues (Details) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues	$ 1,868	$ 1,728
Subscription and Advertisement to Other Revenes [Member]
Revenues	$ 37

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Disaggregated by Geographical Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Total revenues	$ 1,868	$ 1,728
United States [Member]
Total revenues	1,184	986
Foreign [Member]
Total revenues	$ 684	$ 742

Selected Balance Sheet Compon_3

Selected Balance Sheet Components (Details Narrative) - USD ($) $ in Thousands	Aug. 13, 2018	Dec. 31, 2020	Dec. 31, 2019
Depreciation and amortization expense		$ 1,123	$ 393
Accumulated depreciation and amortization		381	554
Depreciation expense		$ 699	91
Payment for patents, description		In addition to the purchase price, AgeX will pay Escape a royalty of less than 1% on net sales of products, processes and services under the acquired patents, if the assets are commercialized. Additional shares of AgeX common stock totaling up to $4.3 million of market value will also be issued to Escape upon the attainment of development and regulatory approval milestones by AgeX for each product covered by the acquired patents.
Royalty percentage		1.00%
Number of common stock issued or Issuable		$ 4,300
Amortization of intangible assets		559	$ 558
Asset Purchase Agreement [Member]
Payments to acquire businesses	$ 1,072,436
Number of shares issued for aquired, shares	80,000
Number of shares issued for aquired	$ 240
Aggregate of acquisition cost	$ 1,300
Laboratory Equipment [Member]
Accumulated depreciation and amortization		21
Depreciation expense		210
Write off of Right-of-Use Assets [Member]
Accumulated depreciation and amortization		726
Leasehold Improvements [Member]
Accumulated depreciation and amortization		436
Other Fixed Asset [Member]
Write off of assets		112
Office Furniture and Equipment [Member]
Write off of assets		$ 89
Research and Development [Member]
Estimated useful lives		P10Y
Consulting fees and services		$ 200

Selected Balance Sheet Compon_4

Selected Balance Sheet Components - Schedule of Property and Equipment, Net, and Construction in Progress (Details) - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Equipment, furniture and fixtures		$ 381	$ 954
Right-of-use assets	[1]		726
Accumulated depreciation and amortization		(381)	(554)
Property and equipment, net			$ 1,126

[1]	AgeX adopted ASC 842 on January 1, 2019. For additional information on this standard and right-of-use assets and liabilities, see Notes 2 and 8.

Selected Balance Sheet Compon_5

Selected Balance Sheet Components - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Intangible assets	$ 5,586	$ 5,586
Accumulated amortization	(3,994)	(3,435)
Intangible assets, net	$ 1,592	$ 2,151

Selected Balance Sheet Compon_6

Selected Balance Sheet Components - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Accounts payable	$ 761	$ 420
Accrued compensation	228	263
Accrued vendors and other expenses	667	899
Accounts payable and accrued liabilities	$ 1,656	$ 1,582

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Dec. 31, 2020	Jul. 27, 2020	Mar. 30, 2020	Aug. 13, 2019	Mar. 18, 2019	Oct. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Aug. 17, 2017
Value of common stock shares issued							$ 37,000	$ 56,000
Chief Operating Officer [Member]
Related party payables	$ 71,000						71,000	71,000
Transactions fixed annual amount						$ 280,000
Alfred D. Kingsley [Member]
Warrants to purchase of common stock					248,600
Warrants exercise price					$ 2.50
Payment of warrants					$ 621,500
Lineage [Member]
Related party payables								$ 7,000
Shared Facilities and Service Agreement [Member]
Allocated cost percentage									5.00%
New Loan Agreement [Member]
Line of credit, maximum borrowing capacity			$ 8,000,000
Stock issued during period, shares		28,500	28,500
Additional loan amount			$ 1,000,000
Line of credit, term			18 months
Line of credit, expiration date			Mar. 30, 2023
Default amount	1,000,000						$ 1,000,000
New Loan Agreement [Member] \| Juvenescence's Discretion [Member]
Line of credit, maximum borrowing capacity			$ 1,000,000
Line of credit borrowed money in excess			500,000
Borrowed an aggregate amount			$ 3,000,000
2019 Loan Agreement [Member] \| Juvenescence [Member]
Line of credit borrowed money in excess				$ 100,000
Line of credit, term				18 months
Line of credit outstanding amount	$ 2,000,000
Related party transaction description				On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the "2019 Loan Agreement") pursuant to which Juvenescence has provided to AgeX a $2.0 million line of credit for a period of 18 months. As of December 31, 2020, AgeX had drawn the full $2.0 million line of credit.
Line of credit facility				$ 2,000,000
Increase in line of credit				$ 4,000,000
Number of common stock shares issued				19,000
Value of common stock shares issued				$ 56,000
Related party transaction percent				10.00%
Gross proceeds from sale of common stock				$ 7,500,000
Line of credit borrowed money in excess not paid				$ 25,000
Warrants to purchase of common stock				150,000
Warrants exercise price				$ 2.60
Warrants, value				$ 236,000
Number of shares issuable				19,000
Issuance of warrants				150,000

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transactions (Details) - Lineage [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Total Use Fees	$ 940
Research and Development [Member]
Total Use Fees	701
General and Administrative [Member]
Total Use Fees	$ 239

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Aug. 13, 2019	Mar. 18, 2019	Jul. 10, 2018	Feb. 28, 2018	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, shares authorized					5,000,000	5,000,000
Preferred stock, par value					$ 0.0001	$ 0.0001
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares authorized					100,000,000	100,000,000
Common stock, par value					$ 0.0001	$ 0.0001
Common stock, shares issued					37,691,000	37,649,000
Common stock, shares outstanding					37,691,000	37,649,000
Alfred D. Kingsley [Member]
Sale of warrants purchase of common stock		248,600
Warrants exercise price		$ 2.50
Juvenescence [Member] \| 2019 Loan Agreement [Member]
Sale of warrants purchase of common stock	150,000
Number of common stock shares issued	19,000
Warrants exercise price	$ 2.60
Warrants [Member]
Proceeds from loans					$ 5,500,000
Sale of warrants purchase of common stock		1,800,000	526,400	1,473,600	2,769,299
Number of common stock shares issued					28,500
Warrants exercise price		$ 2.50	$ 0.50	$ 0.50
Aggregate cash proceed from warrants		$ 4,500,000	$ 263,200	$ 736,800
Warrants [Member] \| Alfred D. Kingsley [Member]
Aggregate cash proceed from warrants				$ 124,300

Stock-Based Awards (Details Nar

Stock-Based Awards (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Options exercisable	$ 2
Number of options exercised
Options granted and outstanding exercised	$ 7,200
Total unrecognized compensation expense	$ 1,500
Recognized over weighted average period	2 years 4 days
Intrinsic value outstanding	$ 239
Weighted-average estimated fair value of stock options granted	$ 0.53	$ 2.45
Stock Options [Member]
Granted options description	In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of AgeX stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years.
Stock Appreciation Rights (SARs) [Member]
Granted options description	The exercise price of an SAR shall not be less than 100% of the fair market value of one share of common stock on the date of grant.
Stock options expiration	10 years
Maximum [Member] \| Restricted Stock and Restricted Stock Units [Member]
Granted options description	They may purchase or otherwise acquire Restricted Stock or Restricted Stock Units subject to such vesting, transfer, and repurchase terms, and other restrictions. The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value.
Minimum [Member] \| Stock Options [Member]
Options exercisable	$ 100
2017 Equity Incentive Plan [Member]
Number of common stock reserved	4,000,000
Granted options description	No person shall be granted, during any one year period, options to purchase, or SARs with respect to, more than 1,000,000 shares in the aggregate, or any Awards of Restricted Stock or Restricted Stock Units with respect to more than 500,000 shares in the aggregate. If an Award is to be settled in cash, the number of shares on which the Award is based shall not count toward the individual share limit.
2017 Equity Incentive Plan [Member] \| Maximum [Member]
Options to purchase shares	1,000,000
2017 Equity Incentive Plan [Member] \| Maximum [Member] \| Restricted Stock Units [Member]
Options to purchase shares	500,000

Stock-Based Awards - Summary of

Stock-Based Awards - Summary of Stock Option Activity (Details) - Equity Incentive Plan [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of RSUs Outstanding, Beginning balance	50,000
Number of RSUs Outstanding, Restricted stock units granted		50,000
Number of RSUs Outstanding, Options granted
Number of RSUs Outstanding, Options expired/forfeited
Number of RSUs Outstanding, Restricted stock units vested	(22,000)
Number of RSUs Outstanding, Ending balance	28,000	50,000
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, Beginning balance	1,054,000	1,731,000
Shares Available for Grant, Restricted stock units granted		(100,000)
Shares Available for Grant, Options granted	(303,000)	(677,000)
Shares Available for Grant, Options expired/forfeited	295,000	100,000
Shares Available for Grant, Restricted stock units vested
Shares Available for Grant, Ending balance	1,046,000	1,054,000
Number of Options Outstanding, Beginning balance	2,846,000	2,269,000
Number of Options Outstanding, Restricted stock units granted
Number of Options Outstanding, Options granted	303,000	677,000
Number of Options Outstanding, Options expired/forfeited	(295,000)	(100,000)
Number of Options Outstanding, Restricted stock units vested
Number of Options Outstanding, Ending balance	2,854,000	2,846,000
Number of Options Outstanding, Exercisable, Ending balance	1,954,000
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 2.74	$ 2.42
Weighted Average Exercise Price, Restricted stock units granted
Weighted Average Exercise Price, Options granted	0.74	3.92
Weighted Average Exercise Price, Options expired/forfeited	2.89	3.48
Weighted Average Exercise Price, Restricted stock units vested
Weighted Average Exercise Price, Outstanding, Ending balance	2.51	$ 2.74
Weighted Average Exercise Price, Eercisable, Ending balance	$ 2.59

Stock-Based Awards - Schedule o

Stock-Based Awards - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 933	$ 1,907
Research and Development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	82	133
General and Administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 851	$ 1,774

Stock-Based Awards - Schedule_2

Stock-Based Awards - Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Expected life (in years)	6 years 29 days	6 years 4 days
Risk-free interest rates	0.45%	1.96%
Volatility	87.86%	74.53%
Dividend yield	0.00%	0.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Aug. 30, 2018	Mar. 23, 2018	Dec. 31, 2020	Dec. 31, 2019
Net operating loss carryforwards for federal tax purposes			$ 49,200,000
Net operating loss carryforwards			2,700,000
Cash received from related party		$ 3,200,000
Gain sale of equity method investment		3,200,000		$ 354,000
Taxable gain		2,200,000
Close merger cash amount		$ 955,000
Proceeds from the sale of investment				354,000
Research and development tax credit carryforwards			$ 2,306,000	2,069,000
Domestic [Member]
Net operating losses expiration date, description			The federal tax credits expire between 2028 and 2040, while the state tax credits have no expiration date.
Research and development tax credit carryforwards			$ 1,300,000
State [Member]
Net operating losses expiration date, description			The federal tax credits expire between 2028 and 2040, while the state tax credits have no expiration date.
Research and development tax credit carryforwards			$ 1,000,000
GILTI [Member]
Income tax rate deduction			50.00%
Other Income Tax Matters [Member]
Income tax description			Internal Revenue Code Section 382 places a limitation ("Section 382 Limitation") on the amount of taxable income that can be offset by net operating loss ("NOL") carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation.
California Purposes [Member]
Net operating loss carryforwards for federal tax purposes			$ 41,000,000
Net operating losses expiration date, description			Federal net operating losses generated on or prior to December 31, 2017, expire in varying amounts between 2028 and 2037, while federal net operating losses generated after December 31, 2017, carryforward indefinitely. The state net operating losses expire in varying amounts between 2028 and 2040.
Lineage [Member]
Percentage of ownership before transaction	80.40%
Percentage of ownership after transaction	40.20%
Juvenescence Limited [Member]
Sale of common stock	14,400,000
Ownership interest	5.60%
Percentage of ownership before transaction	5.60%
Percentage of ownership after transaction	45.80%
LifeMap Sciences [Member]
Net operating loss carryforwards for federal tax purposes			$ 8,900,000
Net operating loss carryforwards			$ 6,200,000
Ascendance [Member] \| Stockholders [Member]
Proceeds from the sale of investment				$ 354,000

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net Loss from Continuing Operations Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net loss before income tax provision	$ (11,126)	$ (12,236)
Domestic [Member]
Net loss before income tax provision	(9,358)	(13,051)
Foreign [Member]
Net loss before income tax provision	$ (1,768)	$ 815

Income Taxes - Schedule of Curr

Income Taxes - Schedule of Current and Deferred Tax Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Current tax provision: U.S. federal
Current tax provision: State
Current tax provision: Foreign	(150)	148
Total current provision	(150)	148
Deferred tax provision (benefit): U.S. federal
Deferred tax provision (benefit): State
Deferred tax provision (benefit): Foreign
Total deferred provision (benefit)
Provision (benefit) for income taxes	$ (150)	$ 148

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 13,958	$ 12,402
Research and development credit carryforwards	2,306	2,069
Patents and fixed assets	693	454
Stock-based compensation	687	659
Operating lease liability		428
Other, net	184	124
Operating lease ROU assets		(424)
Valuation allowance	(17,828)	(15,712)
Total net deferred tax assets

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Computed tax benefit at federal statutory rate	21.00%	21.00%
Research and development and other credits	1.00%	1.00%
State tax benefit, net of effect on federal income taxes	2.00%	5.00%
Permanent differences	(2.00%)	0.00%
Tax effect attributable to foreign operations	(2.00%)	0.00%
Change in valuation allowance	(19.00%)	(28.00%)
Income tax rate	1.00%	(1.00%)

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)		Apr. 13, 2020USD ($)	Apr. 02, 2019USD ($)ft²	Dec. 31, 2019USD ($)ft²	Feb. 17, 2021USD ($)	Dec. 31, 2020USD ($)	Apr. 30, 2019USD ($)
Right-of-use asset	[1]			$ 726,000
Axos Bank [Member] \| Paycheck Protection Program [Member]
Loan obtained		$ 432,952
Interest rate		1.00%
Loan maturity date		Apr. 13, 2022
Notice of Delisting		On June 1, 2020, AgeX received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange's continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the "Compliance Plan") advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange's continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan. The Exchange staff will review AgeX's compliance with the Compliance Plan on a quarterly basis and if AgeX does not show progress consistent with the Compliance Plan or is not in compliance with the Exchange's continued listing standards by December 1, 2021, the Exchange will commence delisting procedures. If the Exchange staff determines that AgeX is not in compliance with the Compliance Plan at any time, the Exchange staff will promptly initiate delisting proceedings.
Accounting Standards Update 2016-02 [Member]
Right-of-use asset							$ 726,000
Right-of-use liability							$ 726,000
Lease Agreement [Member]
Area of land \| ft²			23,911
Base rent			$ 35,867
Increase in base rent			$ 36,943
Lease expiration			Dec. 31, 2020
Tenant improvement expenses				$ 436,000
SubLease Agreement [Member]
Area of land \| ft²				11,121
Base rent				$ 16,312
Lease expiration				Dec. 31, 2020
SubLease Agreement [Member] \| First Sublessee [Member]
Base rent				$ 3,089
SubLease Agreement [Member] \| Second Sublessee [Member]
Base rent				$ 15,405
Immediate Action Agreement [Member] \| Paycheck Protection Program [Member] \| Subsequent Event [Member]
Loan obtained					$ 150,000

[1]	AgeX adopted ASC 842 on January 1, 2019. For additional information on this standard and right-of-use assets and liabilities, see Notes 2 and 8.

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Operating Lease (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating cash flows for operating lease	$ 441	$ 323

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Operating Lease (Details) - USD ($) $ in Thousands	Dec. 31, 2020	[1]	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Right-of-use asset, net			$ 424
Right-of-use lease liability			$ 428
Weighted average remaining lease term, Operating lease	0 years		1 year
Weighted average discount rate, Operating lease	6.00%		6.00%

[1]	The right-of-use asset and right-of-use lease liability were fully amortized and written off as of December 31, 2020 upon termination of the AgeX Lease.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Mar. 06, 2021USD ($)	Feb. 10, 2021USD ($)	Jan. 08, 2021USD ($)$ / shares	Jan. 02, 2021USD ($)ft²	Jan. 31, 2021USD ($)	Mar. 26, 2021USD ($)	Mar. 02, 2021	Dec. 31, 2020$ / shares	Dec. 31, 2019$ / shares	Aug. 30, 2018
Common stock, par value \| $ / shares								$ 0.0001	$ 0.0001
Juvenescence Limited [Member]
Common stock owns percentage										5.60%
Subsequent Event [Member]
Proceeds from offering price						$ 496,000
Subsequent Event [Member] \| Pre-Merger Stockholders [Member]
Percentage on economic interest proposed merger							80.00%
Subsequent Event [Member] \| Juvenescence Limited [Member]
Common stock owns percentage							52.70%
Subsequent Event [Member] \| LyGenesis [Member]
Common stock owns percentage							48.00%
Subsequent Event [Member] \| 2020 Loan Agreement [Member]
Increase in line of credit					$ 2,000,000
Debt maturity date					Mar. 30, 2023
Subsequent Event [Member] \| Amendment to 2019 Loan Agreement [Member]
Increase in line of credit		$ 6,000,000
Loans payable		$ 2,000,000
Loan facility description		The Amendment extends the maturity date of loans under the 2019 Loan Agreement to February 14, 2022 and increases the amount of the loan facility from $2.0 million to $6.0 million, of which AgeX has previously borrowed $2 million. All loans in excess of the initial $2.0 million that AgeX previously borrowed are subject to Juvenescence's discretion. Additional loans, if made, will be in denominations of $1.0 million.
Debt description		AgeX common stock at the time of funding the applicable advance being converted, may not exceed 19.9% of the shares outstanding at August 13, 2019, and (b) no advances may be converted into common stock in an amount that would cause Juvenescence's ownership of AgeX common stock to equal or exceed 50% of the number of shares of AgeX common stock then outstanding.
Subsequent Event [Member] \| Amendment to 2019 Loan Agreement [Member] \| Juvenescence Limited [Member]
Origination fee		$ 160,000
Subsequent Event [Member] \| Merger Agreement [Member]
Payment of merger consideration on pro rata portion	$ 466,400
Conversion of shares of common stock, value	1,761,296
Subsequent Event [Member] \| Merger Agreement [Member] \| LifeMap Sciences [Member]
Payment of merger consideration on pro rata portion	500,000
Indebtedness cash	$ 250,000
Subsequent Event [Member] \| Sales Agreement [Member] \| Chardan Capital Markets LLC [Member]
Common stock, par value \| $ / shares			$ 0.0001
Proceeds from offering price			$ 12,600,000
Subsequent Event [Member] \| Office and Research [Member]
Area of land \| ft²				135
Monthly rent				$ 947,000
Lease term				1 year